<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1250" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1250/" /><meta name="ncbi_pagename" content="Cystic Fibrosis and Congenital Absence of the Vas Deferens - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Cystic Fibrosis and Congenital Absence of the Vas Deferens - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Cystic Fibrosis and Congenital Absence of the Vas Deferens" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/02/02" /><meta name="citation_author" content="Thida Ong" /><meta name="citation_author" content="Susan G Marshall" /><meta name="citation_author" content="Barbara A Karczeski" /><meta name="citation_author" content="Darci L Sternen" /><meta name="citation_author" content="Edith Cheng" /><meta name="citation_author" content="Garry R Cutting" /><meta name="citation_pmid" content="20301428" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1250/" /><meta name="citation_keywords" content="Congenital Absence of the Vas Deferens" /><meta name="citation_keywords" content="Cystic Fibrosis" /><meta name="citation_keywords" content="Cystic fibrosis transmembrane conductance regulator" /><meta name="citation_keywords" content="CFTR" /><meta name="citation_keywords" content="Cystic Fibrosis and Congenital Absence of the Vas Deferens" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Cystic Fibrosis and Congenital Absence of the Vas Deferens" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Thida Ong" /><meta name="DC.Contributor" content="Susan G Marshall" /><meta name="DC.Contributor" content="Barbara A Karczeski" /><meta name="DC.Contributor" content="Darci L Sternen" /><meta name="DC.Contributor" content="Edith Cheng" /><meta name="DC.Contributor" content="Garry R Cutting" /><meta name="DC.Date" content="2017/02/02" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1250/" /><meta name="description" content="Cystic fibrosis (CF) is a multisystem disease affecting epithelia of the respiratory tract, exocrine pancreas, intestine, hepatobiliary system, and exocrine sweat glands. Morbidities include progressive obstructive lung disease with bronchiectasis, frequent hospitalizations for pulmonary disease, pancreatic insufficiency and malnutrition, recurrent sinusitis and bronchitis, and male infertility. Pulmonary disease is the major cause of morbidity and mortality in CF. Meconium ileus occurs at birth in 15%-20% of newborns with CF. More than 95% of males with CF are infertile." /><meta name="og:title" content="Cystic Fibrosis and Congenital Absence of the Vas Deferens" /><meta name="og:type" content="book" /><meta name="og:description" content="Cystic fibrosis (CF) is a multisystem disease affecting epithelia of the respiratory tract, exocrine pancreas, intestine, hepatobiliary system, and exocrine sweat glands. Morbidities include progressive obstructive lung disease with bronchiectasis, frequent hospitalizations for pulmonary disease, pancreatic insufficiency and malnutrition, recurrent sinusitis and bronchitis, and male infertility. Pulmonary disease is the major cause of morbidity and mortality in CF. Meconium ileus occurs at birth in 15%-20% of newborns with CF. More than 95% of males with CF are infertile." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1250/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/cf/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1250/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CA65CE03FD1610000000009F90388.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1250_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1250_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/creatine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ctns/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1250_"><span class="title" itemprop="name">Cystic Fibrosis and Congenital Absence of the Vas Deferens</span></h1><p class="contrib-group"><span itemprop="author">Thida Ong</span>, MD, <span itemprop="author">Susan G Marshall</span>, MD, <span itemprop="author">Barbara A Karczeski</span>, MS, CGC, <span itemprop="author">Darci L Sternen</span>, MS, LGC, <span itemprop="author">Edith Cheng</span>, MS, MD, and <span itemprop="author">Garry R Cutting</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1250_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1250_ai__"><div class="contrib half_rhythm"><span itemprop="author">Thida Ong</span>, MD<div class="affiliation small">Division of Pulmonary and Sleep Medicine<br />Seattle Children's Hospital<br />University of Washington School of Medicine<br />Seattle, Washington</div></div><div class="contrib half_rhythm"><span itemprop="author">Susan G Marshall</span>, MD<div class="affiliation small">Division of Pulmonary and Sleep Medicine<br />Seattle Children's Hospital<br />University of Washington School of Medicine<br />Seattle, Washington</div></div><div class="contrib half_rhythm"><span itemprop="author">Barbara A Karczeski</span>, MS, CGC<div class="affiliation small">DNA Diagnostic Laboratory<br />Johns Hopkins University School of Medicine<br />Baltimore, Maryland</div></div><div class="contrib half_rhythm"><span itemprop="author">Darci L Sternen</span>, MS, LGC<div class="affiliation small">Department of Laboratories and Pediatric Laboratory Utilization Guidance Services<br />Seattle Children's Hospital<br />Seattle, Washington</div></div><div class="contrib half_rhythm"><span itemprop="author">Edith Cheng</span>, MS, MD<div class="affiliation small">Department of Obstetrics and Gynecology<br />University of Washington School of Medicine <br />Seattle, Washington</div></div><div class="contrib half_rhythm"><span itemprop="author">Garry R Cutting</span>, MD<div class="affiliation small">Institute of Genetic Medicine<br />Departments of Pediatrics and Medicine<br />Johns Hopkins University School of Medicine <br />Baltimore, Maryland</div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 26, 2001</span>; Last Update: <span itemprop="dateModified">February 2, 2017</span>.</p><p><em>Estimated reading time: 33 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="cf.Summary" itemprop="description"><h2 id="_cf_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Cystic fibrosis (CF) is a multisystem disease affecting epithelia of the respiratory tract, exocrine pancreas, intestine, hepatobiliary system, and exocrine sweat glands. Morbidities include progressive obstructive lung disease with bronchiectasis, frequent hospitalizations for pulmonary disease, pancreatic insufficiency and malnutrition, recurrent sinusitis and bronchitis, and male infertility. Pulmonary disease is the major cause of morbidity and mortality in CF. Meconium ileus occurs at birth in 15%-20% of newborns with CF. More than 95% of males with CF are infertile.</p><p>Congenital absence of the vas deferens (CAVD) is generally identified during evaluation of infertility or as an incidental finding at the time of a surgical procedure. Hypoplasia or aplasia of the vas deferens and seminal vesicles may occur either bilaterally or unilaterally. Testicular development and function and spermatogenesis are usually normal.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of CF is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with one or more characteristic phenotypic features and evidence of an abnormality in cystic fibrosis transmembrane conductance regulator (CFTR) function (e.g., 2 elevated sweat chloride values, <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>CFTR</i> pathogenic variants, or transepithelial nasal potential difference measurement characteristic of CF). The diagnosis of CF is established in an infant with elevated trypsinogen on <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> and identification of biallelic <i>CFTR</i> pathogenic variants or an elevated sweat chloride.</p><p>The diagnosis of CAVD is established in a male with azoospermia and absence of the vas deferens on palpation or identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> CAVD-causing <i>CFTR</i> pathogenic variants.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment of respiratory complications using inhaled dornase alfa, inhaled hypertonic saline, antibiotics, anti-inflammatory agents, ivacaftor, ivacaftor/lumacaftor combined therapy, lung or heart/lung transplant; topical steroids, antibiotics and/or surgical intervention for nasal/sinus symptoms; treatment of exocrine pancreatic insufficiency using oral pancreatic enzyme replacement, special infant formulas, supplemental nutrition, fat-soluble vitamin supplements and zinc; management of CF-related diabetes mellitus (CFRD) by an endocrinologist; surgical management for meconium ileus; oral ursodiol for biliary sludging/obstruction, liver transplant when indicated; assisted reproductive technologies (ART) for male infertility.</p><p><i>Prevention of primary complications:</i> Airway clearance techniques, dornase alpha, hypertonic saline, antibiotics to prevent chronic airway infection, immunizations including anti-RSV monoclonal antibody; physical activity to maintain bone health and improve airway clearance; nutritional support for pancreatic insufficiency; extra salt and water in hot, dry climates.</p><p><i>Surveillance:</i> Frequent visits to CF care providers to monitor for changes in symptoms and physical examination; cultures of respiratory tract secretions at least four times yearly; pulmonary function studies, chest radiographic examination, annual electrolytes, fat-soluble vitamin levels and IgE levels; bronchoscopy and chest CT examination when indicated; monitor weight gain and caloric intake in infants until age six months; fecal elastase when indicated; annual oral glucose tolerance test in individuals older than age ten years; evaluation of bone mineral density starting in adolescence; annual liver function tests and liver ultrasound to monitor progression of liver disease.</p><p><i>Agents/circumstances to avoid:</i> Respiratory irritants; individuals with respiratory infections; dehydration.</p><p><i>Evaluation of relatives at risk:</i> Molecular genetic testing of at-risk sibs if the pathogenic variants in the family are known or sweat chloride testing of at-risk sibs if the pathogenic variants in the family are not known, to identify as early as possible those who should be referred to a cystic fibrosis center for initiation of treatment and preventive measures.</p><p><i>Therapies under investigation:</i> Prophylactic ursodiol therapy; CF corrector VX-661; inhaled dry powder mannitol; <i>CFTR</i> <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a>.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>CF and CAVD are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with CF and brothers of a male with CAVD have a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <i>CFTR</i> pathogenic variants in the family are known.</p></div></div><div id="cf.Diagnosis"><h2 id="_cf_Diagnosis_">Diagnosis</h2><div id="cf.Suggestive_Findings"><h3>Suggestive Findings</h3><p><b>Cystic fibrosis (CF) should be suspected</b> in individuals with the following features:</p><ul><li class="half_rhythm"><div>Chronic sinopulmonary disease including chronic cough and sputum production, chronic wheeze and air trapping, obstructive lung disease on pulmonary function tests, persistent colonization with pathogens commonly found in individuals with CF, persistent chest radiograph abnormalities, nasal polyps, chronic pan sinusitis, and digital clubbing</div></li><li class="half_rhythm"><div>Gastrointestinal/nutritional abnormalities such as meconium ileus, rectal prolapse, malabsorption/pancreatic insufficiency, steatorrhea, distal intestinal obstructive syndrome, recurrent acute pancreatitis, chronic pancreatitis, prolonged neonatal jaundice, chronic hepatic disease manifested by clinical or histologica evidence of focal biliary cirrhosis or multilobular cirrhosis, failure to thrive (protein-calorie malnutrition), hypoproteinemia and edema, complications secondary to fat-soluble vitamin deficiencies</div></li><li class="half_rhythm"><div>Obstructive azoospermia</div></li><li class="half_rhythm"><div>Salt-loss syndromes including acute salt depletion, chronic metabolic alkalosis, and hyponatremic hypochloremic dehydration</div></li><li class="half_rhythm"><div>In infants: elevated immunoreactive trypsinogen (IRT) on <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a></div></li></ul><p><b>Congenital absence of the vas deferens (CAVD) should be suspected</b> in males with the following:</p><ul><li class="half_rhythm"><div>Severe oligospermia or azoospermia</div></li><li class="half_rhythm"><div>A low volume of ejaculated semen with a specific chemical profile (low pH, elevated citric acid concentration, elevated acid phosphatase concentration, low fructose concentration, and failure to coagulate)</div></li><li class="half_rhythm"><div>Evidence of abnormalities of seminal vesicles or vas deferens on rectal ultrasound examination</div></li></ul></div><div id="cf.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>The diagnosis of CF</b>
<b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the following:</p><ul><li class="half_rhythm"><div>One or more characteristic phenotypic features of CF and evidence of an abnormality in cystic fibrosis transmembrane conductance regulator (CFTR) function based on ONE of the following:</div><ul><li class="half_rhythm"><div>Two abnormal quantitative pilocarpine iontophoresis sweat chloride values (&#x0003e;60 mEq/L in infants age &#x0003e; 6 months). Click <a href="/books/NBK1250/bin/cf-dx_tests.pdf">here</a> (pdf) for more specific information on this test.</div></li><li class="half_rhythm"><div>Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic or likely pathogenic variants in <i>CFTR</i> (see <a class="figpopup" href="/books/NBK1250/table/cf.T.molecular_genetic_testing_used_in_c/?report=objectonly" target="object" rid-figpopup="figcfTmoleculargenetictestingusedinc" rid-ob="figobcfTmoleculargenetictestingusedinc">Table 1</a>)</div></li><li class="half_rhythm"><div>Transepithelial nasal potential difference measurements characteristic of CF. Click <a href="/books/NBK1250/bin/cf-dx_tests.pdf">here</a> (pdf) for more specific information on this test.</div></li></ul></li><li class="half_rhythm"><div>In an infant: elevated trypsinogen on <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> immunoreactive trypsinogen (IRT) assay AND</div><ul><li class="half_rhythm"><div>Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> CF-causing pathogenic variants in <i>CFTR</i></div><div>OR</div></li><li class="half_rhythm"><div>An abnormal sweat chloride value &#x02265;60 mEq/L (see <a href="http://www.acmg.net/PDFLibrary/Cystic-Fibrosis-ACT-Sheet.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACMG Newborn Screening ACT Sheet</a>)</div></li></ul></li></ul><p><b>The diagnosis of CAVD is established</b> in a male with the following features:</p><ul><li class="half_rhythm"><div>Azoospermia</div><div>AND</div></li><li class="half_rhythm"><div>Absence of the vas deferens on palpation (rarely, a thin fibrous cord representing a rudimentary vas deferens may be present)</div><div>OR</div></li><li class="half_rhythm"><div>Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> CAVD-causing <i>CFTR</i> pathogenic variants (establishes the diagnosis if clinical features are inconclusive; see <a class="figpopup" href="/books/NBK1250/table/cf.T.molecular_genetic_testing_used_in_c/?report=objectonly" target="object" rid-figpopup="figcfTmoleculargenetictestingusedinc" rid-ob="figobcfTmoleculargenetictestingusedinc">Table 1</a>)</div></li></ul><p>Molecular genetic testing approaches include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Targeted analysis for <i>CFTR</i> pathogenic variants can be performed first.</div><div class="half_rhythm">Note: The American College of Medical Genetics recommended panel includes the 23 pathogenic variants listed in <a class="figpopup" href="/books/NBK1250/table/cf.T.recommended_panel_of_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figcfTrecommendedpanelofpathogenicvar" rid-ob="figobcfTrecommendedpanelofpathogenicvar">Table 6</a> and has a detection rate of 97% in <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a>, 88.3% in non-Hispanic whites, 69% in African Americans, and 57% in Hispanic Americans; detection rate in Asian Americans is unknown [<a class="bk_pop" href="#cf.REF.grody.2001">Grody et al 2001</a>, <a class="bk_pop" href="#cf.REF.palomaki.2002.90">Palomaki et al 2002</a>, <a class="bk_pop" href="#cf.REF.watson.2004.387">Watson et al 2004</a>].</div><div class="half_rhythm">Note: A panel that includes more than 129 pathogenic variants would detect approximately 96% of pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals (see <a href="http://www.cftr2.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cftr2.org</a>) [<a class="bk_pop" href="#cf.REF.sosnay.2013.1160">Sosnay et al 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Sequence analysis of <i>CFTR</i> &#x02013; followed by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> &#x02013; is performed if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div><div class="half_rhythm">Note: Sequence analysis of <i>CFTR</i>, followed by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, is the initial diagnostic test for:</div><ul><li class="half_rhythm"><div>Individuals of an ethnicity for which the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of targeted analysis is low;</div></li><li class="half_rhythm"><div>Prenatal testing in a high-risk fetus;</div></li><li class="half_rhythm"><div>Prenatal testing in a low-risk fetus with echogenic bowel identified on prenatal ultrasound examination;</div></li><li class="half_rhythm"><div>An infant with an elevated IRT assay on <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> and a sweat chloride of 30-59 mEq/L (intermediate result);</div></li><li class="half_rhythm"><div>A symptomatic infant (e.g., infant with meconium ileus) who is too young to produce adequate volumes of sweat.</div></li></ul></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>CFTR</i> and other genes of interest (see <a href="#cf.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Notes: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="cf.T.molecular_genetic_testing_used_in_c" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Cystic Fibrosis (CF) and Congenital Absence of the Vas Deferens (CAVD)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1250/table/cf.T.molecular_genetic_testing_used_in_c/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cf.T.molecular_genetic_testing_used_in_c_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_2" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr><tr><th headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3" id="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">CF</th><th headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3" id="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CAVD</th></tr></thead><tbody><tr><td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>CFTR</i></td><td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3 hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">97%-98%</td><td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3 hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">79%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3 hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_1 hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">&#x02264;2%-3%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="cf.TF.1.1"><p class="no_margin">See <a href="/books/NBK1250/#cf.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="cf.TF.1.2"><p class="no_margin">See <a href="#cf.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="cf.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="cf.TF.1.4"><p class="no_margin">79% of men had at least one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified, 46% had both <i>CFTR</i> pathogenic variants identified; <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> varied by ethnicity [<a class="bk_pop" href="#cf.REF.yu.2012.25">Yu et al 2012</a>].</p></div></dd><dt>5. </dt><dd><div id="cf.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div></div></div><div id="cf.Clinical_Characteristics"><h2 id="_cf_Clinical_Characteristics_">Clinical Characteristics</h2><div id="cf.Clinical_Description"><h3>Clinical Description</h3><p><b>Cystic fibrosis (CF)</b> affects the epithelia in several organs resulting in a complex, multisystem disease that involves the respiratory tract, exocrine pancreas, intestine, hepatobiliary system, male genital tract, and exocrine sweat glands. Morbidities include progressive obstructive lung disease with bronchiectasis, frequent hospitalizations for pulmonary disease, pancreatic insufficiency and malnutrition, recurrent sinusitis and bronchitis, and male infertility. The overall median predicted survival is estimated at 40.7 years (95% confidence intervals, 37.7- 44.1 yrs) [CFF <a class="bk_pop" href="#cf.REF.patient_registry.2013">Patient Registry 2013</a>].</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Respiratory.</b> Pulmonary disease remains the major cause of morbidity and mortality in CF. Early manifestations are chronic cough, intermittent sputum production, and exertional dyspnea. Bronchiectasis is now known to develop early, detectable in infants as young as age ten weeks, and is persistent and progressive [<a class="bk_pop" href="#cf.REF.sly.2013.1963">Sly et al 2013</a>]. Failure of lung defenses leads to bacterial endobronchitis (most commonly <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i>) with resulting airway obstruction and intense neutrophilic inflammation. Progression of lung disease results in chronic endobronchitis and structural injury to the airways. End-stage lung disease is characterized by extensive damage to the airways (cysts/abscesses) and accompanying fibrosis of lung parenchyma adjacent to airways.</div><div class="half_rhythm">Other respiratory causes of morbidity include recurrent sinusitis and nasal polyposis.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Exocrine pancreatic insufficiency</b> with malabsorption occurs in the great majority of individuals with CF, although median body mass index percentiles have steadily increased [CFF <a class="bk_pop" href="#cf.REF.patient_registry.2013">Patient Registry 2013</a>]. Pancreatic insufficiency is caused by inspissation of secretions within the pancreatic ducts and ultimately interstitial fibrosis. The clinical manifestations are steatorrhea and poor growth related to fat malabsorption. Acute or chronic recurrent pancreatitis can be a presenting manifestation of CF, and is much more common among those with pancreatic sufficiency (10% prevalence) than those with pancreatic insufficiency (0.5% prevalence) [<a class="bk_pop" href="#cf.REF.de_boeck.2005.e463">De Boeck et al 2005</a>]. Hemolytic anemia, defective coagulation, or skin rashes related to deficiencies of fat-soluble vitamins and zinc may occasionally be seen.</div><div class="half_rhythm">Cystic fibrosis-related diabetes (CFRD) can occur at any age, but prevalence increases with age, estimated in 20% of adolescents and 40%-50% of adults [<a class="bk_pop" href="#cf.REF.moran.2009.1626">Moran et al 2009</a>, <a class="bk_pop" href="#cf.REF.moran.2014.65">Moran et al 2014</a>]. CFRD is distinctive from type 1 and type 2 diabetes and requires its own approach to both diagnosis and management [<a class="bk_pop" href="#cf.REF.moran.2014.65">Moran et al 2014</a>]. Glucose metabolism in CFRD is impaired by a loss of total islet cells leading to an absence of insulin and glucagon, and fluctuating insulin resistance occurs from chronic and acute inflammation. CFRD is diagnosed if the fasting glucose level is &#x02265;126 mg/dL (7.0 mmol/L) or the two-hour oral glucose tolerance test glucose level is &#x02265;200 mg/dL (11.1 mmol/L). CFRD can be diagnosed during a pulmonary exacerbation if fasting glucose levels of &#x02265;126 mg/dL (7.0 mmol/L) or the two-hour post prandial levels of &#x02265;200 mg/dL (11.1 mmol/L) persist for 48 hours [<a class="bk_pop" href="#cf.REF.moran.2010.2697">Moran et al 2010</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Gastrointestinal.</b> Meconium ileus occurs in 15%-20% of newborns diagnosed with CF.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Liver disease</b> typically presents by age ten years and is defined as the presence of at least two of the following: hepatomegaly, elevated serum hepatic enzyme levels, and/or liver ultrasound abnormalities other than hepatomegaly [<a class="bk_pop" href="#cf.REF.leeuwen.2014.69">Leeuwen et al 2014</a>]. Liver disease is reported in approximately 10% of individuals [CFF <a class="bk_pop" href="#cf.REF.patient_registry.2013">Patient Registry 2013</a>]. Approximately 5%-10% develop clinically significant liver disease with multilobar cirrhosis and portal hypertension [<a class="bk_pop" href="#cf.REF.debray.2011.s29">Debray et al 2011</a>]. Progression is variable. Individuals with CF may develop focal biliary cirrhosis from progressive portal fibrosis and biliary obstruction. Complications include variceal bleeding, ascites, hypersplenism, hepatic encephalopathy, and rarely liver synthetic failure. Liver disease is the cause of mortality in 2.9% of individuals with CF [CFF <a class="bk_pop" href="#cf.REF.patient_registry.2013">Patient Registry 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Fertility.</b> More than 95% of males with CF are infertile as a result of azoospermia caused by altered vas deferens, which may be absent, atrophic, or fibrotic.</div><div class="half_rhythm">Women with CF are fertile, although a few females have abnormal cervical mucus that may contribute to infertility. Others with severe illness and reduced body mass index may be anovulatory. The rate of live births among females with CF age 14-45 years is 1.6 per 100 [CFF <a class="bk_pop" href="#cf.REF.patient_registry.2011">Patient Registry 2011</a>].</div></li></ul><p><b>Congenital absence of the vas deferens (CAVD)</b> is generally identified during evaluation of infertility or as an incidental finding at the time of a surgical procedure, such as orchidopexy. CAVD accounts for 1.2%-1.7% of male infertility. Hypoplasia or aplasia of the vas deferens and seminal vesicles may occur either bilaterally or unilaterally. Testicular development and function and spermatogenesis are usually normal.</p></div><div id="cf.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The <a href="http://www.cftr2.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical and Functional Translation of CFTR</a> website provides information about <i>CFTR</i> pathogenic variants including sweat chloride, lung function, pancreatic status, and pseudomonas infection rates in individuals with specific pathogenic variants.</p><p><b>Cystic fibrosis.</b> The best correlation between <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is seen in the context of pancreatic function. The most common pathogenic variants have been classified as pancreatic sufficient (PS) or pancreatic insufficient. Individuals with pancreatic sufficiency usually have either one or two PS alleles, indicating that PS alleles are dominant with respect to pancreatic phenotype.</p><p>The severity of pulmonary disease among individuals with identical genotypes varies widely. Limited <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> include:</p><p>Compound heterozygotes for p.Phe508del/p.Ala455Glu have better pulmonary function than individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for p.Phe508del [<a class="bk_pop" href="#cf.REF.de_braekeleer.1997.208">De Braekeleer et al 1997</a>].</p><ul><li class="half_rhythm"><div>The severity of lung disease in individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for p.Arg117His depends on the presence of a variation in the poly T tract of <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 9, c.1210-12T[5_9] [<a class="bk_pop" href="#cf.REF.massie.2001.1195">Massie et al 2001</a>]. Individuals with a CF-causing variant plus the 5T variant <i>in cis</i> with p.Arg117His usually develop the lung disease of CF, but those individuals with p.Arg117His and the 7T variant or the 9T variant have a highly variable <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> that can range from no symptoms to mild lung disease [<a class="bk_pop" href="#cf.REF.kiesewetter.1993.274">Kiesewetter et al 1993</a>, <a class="bk_pop" href="#cf.REF.chmiel.1999.823">Chmiel et al 1999</a>].</div></li><li class="half_rhythm"><div>Because p.Ala455Glu and p.Arg117His are associated with pancreatic sufficiency, the less severe lung disease seen in individuals with these pathogenic variants could be the consequence of better nutritional status.</div></li></ul><p><b>CAVD.</b> CAVD usually results from compound heterozygosity of a classic (severe, <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a>) <i>CFTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> with a mild (retaining some function) <i>CFTR</i> pathogenic variant (e.g., the 5T <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>; <a class="figpopup" href="/books/NBK1250/table/cf.T.genotypephenotype_correlations/?report=objectonly" target="object" rid-figpopup="figcfTgenotypephenotypecorrelations" rid-ob="figobcfTgenotypephenotypecorrelations">Table 2</a>). However, some overlap exists between the CAVD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and a very mild CF phenotype, with a small percentage of individuals with CAVD also reporting respiratory or pancreatic problems [<a class="bk_pop" href="#cf.REF.d_rk.1997.365">D&#x000f6;rk et al 1997</a>, <a class="bk_pop" href="#cf.REF.gilljam.2004.174">Gilljam et al 2004</a>]. The 5T allele may be associated with lung disease in adult females with CF-like clinical features [<a class="bk_pop" href="#cf.REF.noone.2000.1919">Noone et al 2000</a>]. Thus, caution must be exercised in attempting to use <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> to predict the future course of individuals initially diagnosed with CAVD only.</p><div id="cf.T.genotypephenotype_correlations" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Genotype-Phenotype Correlations</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1250/table/cf.T.genotypephenotype_correlations/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cf.T.genotypephenotype_correlations_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;"><i>CFTR</i> Genotype&#x000a0;<sup>1</sup></th><th id="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" style="text-align:left;vertical-align:middle;">Range of Phenotypes&#x000a0;<sup>2</sup></th></tr><tr><th headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1" id="hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">First Allele</th><th headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1" id="hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Second Allele<br />(or Homozygous)</th></tr></thead><tbody><tr><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic (e.g., p.Phe508del)</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic &#x0003e;&#x0003e; non-classic</td></tr><tr><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild (e.g., p.Ala455Glu)</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic or mild</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Non-classic &#x0003e; classic</td></tr><tr><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg117His / 5T</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic or mild</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Non-classic &#x0003e; classic</td></tr><tr><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg117His / 7T</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic or mild</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asymptomatic female or CAVD &#x0003e; non-classic</td></tr><tr><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5T / 13TG or 12TG</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic or mild</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CAVD or non-classic CF &#x0003e;&#x0003e; asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a></td></tr><tr><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5T / 11TG</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic or mild</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asymptomatic &#x0003e; CAVD</td></tr><tr><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7T or 9T</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic or mild</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asymptomatic</td></tr><tr><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7T or 9T</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7T or 9T</td><td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asymptomatic</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="cf.TF.2.1"><p class="no_margin">Patterns reflect dominant effect of "milder" alleles in compound heterozygotes. Classic alleles generally refer to Class I-III pathogenic variants; mild alleles refer to Class IV-V pathogenic variants exclusive of p.Arg117His and 5T alleles (see <a class="figpopup" href="/books/NBK1250/table/cf.T.historical_classification_scheme_fo/?report=objectonly" target="object" rid-figpopup="figcfThistoricalclassificationschemefo" rid-ob="figobcfThistoricalclassificationschemefo">Table 8</a>).</p></div></dd><dt>2. </dt><dd><div id="cf.TF.2.2"><p class="no_margin">Data derived from <a class="bk_pop" href="#cf.REF.kiesewetter.1993.274">Kiesewetter et al [1993]</a>, <a class="bk_pop" href="#cf.REF.witt.1996.823">Witt et al [1996]</a>, <a class="bk_pop" href="#cf.REF.brock.1998.47">Brock et al [1998]</a>, <a class="bk_pop" href="#cf.REF.cuppens.1998.487">Cuppens et al [1998]</a>, <a class="bk_pop" href="#cf.REF.mak.1999.2217">Mak et al [1999]</a>, <a class="bk_pop" href="#cf.REF.wang.2002.2066">Wang et al [2002]</a>, <a class="bk_pop" href="#cf.REF.mckone.2003.1671">McKone et al [2003]</a>, <a class="bk_pop" href="#cf.REF.groman.2004.176">Groman et al [2004]</a></p></div></dd></dl></div></div></div></div><div id="cf.Nomenclature"><h3>Nomenclature</h3><p>Atypical cystic fibrosis, a term originally proposed to describe a disorder that presents with cystic fibrosis-like symptoms but is not caused by CFTR dysfunction, is sometimes used to denote mild or non-classic CF. However, use of the term in this way is confusing and strongly discouraged.</p></div><div id="cf.Prevalence"><h3>Prevalence</h3><p>CF is the most common life-limiting <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder in individuals of northern European background. The disease incidence of CF is 1:3,200 live births in this population [<a class="bk_pop" href="#cf.REF.rosenstein.1998.589">Rosenstein &#x00026; Cutting 1998</a>]. Approximately 30,000 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons live in the United States. The <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of individuals of northern European ancestry living in North America is 1:28 (see <a class="figpopup" href="/books/NBK1250/table/cf.T.carrier_frequency_for_pathogenic_cf/?report=objectonly" target="object" rid-figpopup="figcfTcarrierfrequencyforpathogeniccf" rid-ob="figobcfTcarrierfrequencyforpathogeniccf">Table 3</a>).</p><p>CF occurs with lower frequency in other ethnic and racial populations (1:15,000 African Americans, and 1:31,000 Asian Americans) [<a class="bk_pop" href="#cf.REF.rosenstein.1998.589">Rosenstein &#x00026; Cutting 1998</a>].</p><div id="cf.T.carrier_frequency_for_pathogenic_cf" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Carrier Frequency for Pathogenic <i>CFTR</i> Alleles</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1250/table/cf.T.carrier_frequency_for_pathogenic_cf/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cf.T.carrier_frequency_for_pathogenic_cf_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Population Group</th><th id="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Approximate Carrier Frequency</th><th id="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference</th></tr></thead><tbody><tr><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a></td><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:29</td><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#cf.REF.kerem.1997.35">Kerem et al [1997]</a></td></tr><tr><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">North Americans of northern European background</td><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:28</td><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#cf.REF.hamosh.1998.255">Hamosh et al [1998]</a></td></tr><tr><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">African American</td><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:61</td><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#cf.REF.hamosh.1998.255">Hamosh et al [1998]</a></td></tr><tr><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asian American</td><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:118&#x000a0;<sup>1</sup></td><td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#cf.REF.rohlfs.2011.841">Rohlfs et al [2011]</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="cf.TF.3.1"><p class="no_margin">This <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency is based on observed frequency of pathogenic variants in a tested population; it is not calculated from a population incidence.</p></div></dd></dl></div></div></div></div></div><div id="cf.Genetically_Related_Allelic_Disorders"><h2 id="_cf_Genetically_Related_Allelic_Disorders_">Genetically Related (Allelic) Disorders</h2><p><i>CFTR</i>-related disorder (CFTR-RD) includes <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> pancreatitis and bronchiectasis due to <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>CFTR</i> pathogenic variants in individuals who do not meet clinical diagnostic criteria for CF [<a class="bk_pop" href="#cf.REF.bombieri.2011.s86">Bombieri et al 2011</a>].</p><p><i>CFTR</i>-related metabolic syndrome (CRMS) is used to describe an infant with an elevated trypsinogen on <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>, sweat chloride values &#x02264;60 mEq/L, and up to two <i>CFTR</i> variants, at least one of which is not clearly categorized as a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and therefore not meeting diagnostic criteria for CF. These infants are typically asymptomatic, and knowledge of the natural history of CRMS continues to evolve [<a class="bk_pop" href="#cf.REF.borowitz.2009.s106">Borowitz et al 2009</a>].</p><p>An increased prevalence of <i>CFTR</i> pathogenic variants has been noted in individuals with <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> pancreatitis, bronchiectasis, allergic bronchopulmonary aspergillosis, and chronic rhinosinusitis [<a class="bk_pop" href="#cf.REF.nick.2005.513">Nick &#x00026; Rodman 2005</a>, <a class="bk_pop" href="#cf.REF.weiss.2005.1456">Weiss et al 2005</a>, <a class="bk_pop" href="#cf.REF.bombieri.2011.s86">Bombieri et al 2011</a>, <a class="bk_pop" href="#cf.REF.ferec.2012.a009480">Ferec &#x00026; Cutting 2012</a>].</p></div><div id="cf.Differential_Diagnosis"><h2 id="_cf_Differential_Diagnosis_">Differential Diagnosis</h2><div id="cf.Cystic_Fibrosis_CF"><h3>Cystic Fibrosis (CF)</h3><p><b>Primary dysphagia</b>
<b>with chronic descending tracheal aspiration</b> and <b>primary gastroesophageal reflux (GER) with or without ascending tracheal aspiration.</b> Both conditions can cause chronic cough in infancy and may be associated with failure to thrive. However, in infants without CF, the cough is often temporally associated with feedings; and steatorrhea is not associated with primary dysphagia or primary GER.</p><p><a href="/books/n/gene/x-scid/"><b>Severe combined immunodeficiency</b></a>
<b>and other immunodeficiency disorders.</b> Individuals with immunodeficiency may present with recurrent respiratory infections and chronic diarrhea in infancy. These individuals are also prone to non-respiratory infections (e.g., otitis media, cellulitis) not specifically associated with CF.</p><p><b>Asthma.</b> CF and asthma both present with chronic cough and persistent wheeze following respiratory viral infections, allergen exposure, or exertion. However, individuals with asthma typically improve on asthma therapy, do not experience recurrent pneumonia, are not colonized with CF-related bacteria, have normal growth and weight gain, and do not have steatorrhea.</p><p><b>Congenital airway anomalies</b> can cause chronic cough and wheezing during infancy similar to CF. Gastrointestinal or nutritional manifestations that are typically present in infants with CF are not seen in children with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> airway anomalies. Stridor is not common in CF.</p><p><a href="/books/n/gene/pcd/"><b>Primary ciliary dyskinesia</b></a>
<b>(PCD)</b> is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic oto-sino-pulmonary disease. Individuals with PCD present with respiratory distress in infancy, cough and sputum production with recurrent pneumonias that may progress to chronic bronchiectasis, <i>Pseudomonas aeruginosa</i> or other opportunistic bacterial pathogens that may be cultured from airway secretions, and chronic sinus disease. Situs inversus is present in 50% of individuals with PCD; steatorrhea and failure to thrive are not associated with PCD. PCD is associated with pathogenic variants in multiple genes encoding different structural components of cilia and is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><a href="/books/n/gene/sds/"><b>Shwachman-Diamond syndrome</b></a>
<b>(SDS</b>) is characterized by exocrine pancreatic dysfunction with malabsorption, malnutrition, and growth failure. SDS can be distinguished from CF by the presence of hematologic abnormalities with single- or multilineage cytopenias, susceptibility to myelodysplasia syndrome (MDS) and acute myelogenous leukemia (AML), and skeletal abnormalities (most commonly chondrodysplasia or asphyxiating thoracic dystrophy). SDS is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SBDS</i> and is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><b>Primary biliary atresia.</b> Rarely, individuals with CF may present in infancy with symptoms of biliary obstruction without other clinically apparent GI or respiratory manifestations. Serum levels of immunoreactive trypsinogen and stool levels of elastase should be normal in primary biliary atresia, whereas CF liver disease is invariably associated with evidence of pancreatic duct obstruction.</p><p><b>Bronchiectasis with or without elevated sweat chloride.</b> Pathogenic variants in <i>SCNN1A</i>, <i>SCNN1B</i>, and <i>SCNN1G</i> encoding the beta subunit of the epithelial sodium channel cause a non-classic CF <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#cf.REF.sheridan.2005.3493">Sheridan et al 2005</a>]. Individuals with <i>SCNN1A</i>, <i>SCNN1B</i>, or <i>SCNN1G</i> pathogenic variants may also have mild lung disease and elevated sweat chloride concentration.</p><p><b>Isolated hyperchlorhidrosis,</b> characterized by elevated sweat chloride levels and failure to thrive, is caused by pathogenic variants in <i>CA12</i>, which encodes carbonic anhydrase XII [<a class="bk_pop" href="#cf.REF.feldshtein.2010.713">Feldshtein et al 2010</a>].</p></div><div id="cf.Congenital_Absence_of_the_Vas_Deferen"><h3>Congenital Absence of the Vas Deferens (CAVD)</h3><p>CAVD is part of the differential diagnosis of obstructive azoospermia, caused by obstruction to sperm outflow from the testes or ductular system. Obstructive azoospermia may be part of a syndrome or may be an <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> finding. Syndromes with obstructive azoospermia include the following:</p><ul><li class="half_rhythm"><div><b>Young syndrome</b> (OMIM <a href="http://omim.org/entry/279000" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">279000</a>), a progressive obstruction of the epididymis by inspissated secretions in males with chronic sinopulmonary infection. Males with Young syndrome do not have malformations of the vas deferens or epididymis. Molecular testing of individuals with Young syndrome indicates that this disorder is not caused by pathogenic variants in <i>CFTR</i> [<a class="bk_pop" href="#cf.REF.friedman.1995.1353">Friedman et al 1995</a>].</div></li><li class="half_rhythm"><div><b>Hereditary urogenital adysplasia</b> (OMIM <a href="http://omim.org/entry/277000" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">277000</a>), an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> disorder of <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a> and reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. Females have a range of uterine anomalies; males may have Wolffian duct anomalies including unilateral or bilateral absence of the vas deferens; males and females may have unilateral or bilateral renal agenesis.</div></li></ul></div></div><div id="cf.Management"><h2 id="_cf_Management_">Management</h2><div id="cf.Evaluations_Following_Initial_Diagnos"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <b>cystic fibrosis (CF)</b> the following evaluations are recommended.</p><p><b>Respiratory</b></p><ul><li class="half_rhythm"><div>Sinus CT to assess for pan sinusitis in individuals with chronic nasal congestion and/or recurrent sinusitis</div></li><li class="half_rhythm"><div>Pulmonary function testing (PFT), including infant PFT at specialized centers</div></li><li class="half_rhythm"><div>Chest radiographic examination to screen for bronchiectasis, or chest computed tomography (CT) examination as indicated for worsening symptoms or concern for progression</div></li><li class="half_rhythm"><div>Sputum culture in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who can expectorate a sputum sample, or culture of deep oropharyngeal swab in those who cannot</div></li><li class="half_rhythm"><div>Bronchoscopy with bronchoalveolar lavage to evaluate lower airway microbiology and inflammation as indicated</div></li></ul><p><b>Exocrine pancreatic insufficiency</b></p><ul><li class="half_rhythm"><div>Fecal elastase</div></li><li class="half_rhythm"><div>Fecal fat content based on 72-hour stool collection</div></li><li class="half_rhythm"><div>Vitamin A, D, and E serum concentrations</div></li><li class="half_rhythm"><div>Prothrombin time and international normalized ratio (INR)</div></li><li class="half_rhythm"><div>Random glucose</div></li></ul><p><b>Overall clinical status / extent of disease</b></p><ul><li class="half_rhythm"><div>CBC with differential and cell count</div></li><li class="half_rhythm"><div>Serum electrolytes, BUN, creatinine</div></li><li class="half_rhythm"><div>Liver function tests (ALT, AST)</div></li><li class="half_rhythm"><div>Consultation with a genetic counselor</div></li></ul><p>To establish the extent of disease and needs in an individual diagnosed with <b><a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> absence of the vas deferens (CAVD)</b> referral to a urologist is recommended.</p></div><div id="cf.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="cf.Cystic_Fibrosis_CF_1"><h4>Cystic Fibrosis (CF)</h4><p><b>Respiratory</b></p><ul><li class="half_rhythm"><div>Inhaled dornase alfa in all individuals age &#x02265;6 years</div></li><li class="half_rhythm"><div>Inhaled hypertonic saline in all individuals age &#x02265;6 years</div></li><li class="half_rhythm"><div>Azithromycin in individuals age &#x02265;6 years with persistent <i>Pseudomonas aeruginosa</i> in airway cultures</div></li><li class="half_rhythm"><div>Inhaled tobramycin in individuals age &#x02265;6 years with lung disease (mild, moderate, or severe) and persistent <i>P. aeruginosa</i> in airway cultures</div></li><li class="half_rhythm"><div>Inhaled aztreonam in individuals age &#x02265;6 years with lung disease (mild, moderate, or severe) and persistent <i>P. aeruginosa</i> in airway cultures</div></li><li class="half_rhythm"><div>Ibuprofen in individuals age 6-17 years with FEV<sub>1</sub> &#x02265;60% predicted</div></li><li class="half_rhythm"><div>Recommended sequence for inhaled medications:</div><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin">Bronchodilator</p></dd><dt>2.</dt><dd><p class="no_top_margin">Hypertonic saline</p></dd><dt>3.</dt><dd><p class="no_top_margin">Dornase alfa</p></dd><dt>4.</dt><dd><p class="no_top_margin">Airway clearance</p></dd><dt>5.</dt><dd><p class="no_top_margin">An aerosolized antibiotic</p></dd></dl></li><li class="half_rhythm"><div>Ivacaftor for individuals age &#x02265;2 years who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for p.Gly551Asp and other specific pathogenic variants</div></li><li class="half_rhythm"><div>Ivacaftor/lumacaftor combined therapy for individuals age &#x02265;12 years who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for p.Phe508del</div></li><li class="half_rhythm"><div>Lung or heart/lung transplantation; an option for some individuals with severe disease</div></li><li class="half_rhythm"><div>Topical steroids, antibiotics, and/or surgical intervention if required for nasal/sinus symptoms</div></li></ul><p><b>Exocrine pancreatic insufficiency</b></p><ul><li class="half_rhythm"><div>Oral pancreatic enzyme replacement with meals</div></li><li class="half_rhythm"><div>Nutritional therapy that may include breast milk, special infant formulas, supplemental feeding, salt supplementation, fat-soluble vitamin supplements, and zinc</div></li><li class="half_rhythm"><div>Management of CF-related diabetes mellitus with endocrinology consultation and (if required) glucose monitoring and insulin therapy</div></li></ul><p><b>Gastrointestinal.</b> Meconium ileus and distal intestinal obstructive syndrome requires surgical evaluation and management.</p><p><b>Liver disease</b></p><ul><li class="half_rhythm"><div>Biliary sludging or frank obstruction, and associated hepatic inflammation, are treated with oral ursodiol.</div></li><li class="half_rhythm"><div>Liver transplant indications include progressive hepatic dysfunction, intractable variceal bleeding, and hepatopulmonary and portopulmonary syndromes</div></li></ul><p><b>Fertility.</b> Assisted reproductive technologies include microscopic sperm aspiration from the epididymal remnant in conjunction with in vitro fertilization or artificial insemination using donor sperm.</p></div><div id="cf.Congenital_Absence_of_the_Vas_Deferen_1"><h4>Congenital Absence of the Vas Deferens (CAVD)</h4><p>Assisted reproductive technologies include microscopic sperm aspiration from the epididymal remnant in conjunction with in vitro fertilization or artificial insemination using donor sperm.</p></div></div><div id="cf.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations &#x02013; Cystic Fibrosis</h3><p><b>Respiratory</b></p><ul><li class="half_rhythm"><div class="half_rhythm">A variety of airway clearance techniques (ACTs) can mobilize airway secretions, minimize airway obstruction, and reduce airway infections. ACTs include manual chest percussion with postural drainage, hand-held devices (e.g., flutter valve, or Acapella<sup>&#x000ae;</sup>), and inflatable vest therapy devices that vibrate the chest wall. These treatments are most effective when used at least twice daily.</div></li><li class="half_rhythm"><div class="half_rhythm">Dornase alfa and hypertonic saline help mobilize airway secretions in individuals age six years or older.</div></li><li class="half_rhythm"><div class="half_rhythm">Airway clearance should be used in conjunction with inhaled medications given in a standard sequence:</div><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin">Bronchodilator</p></dd><dt>2.</dt><dd><p class="no_top_margin">Hypertonic saline</p></dd><dt>3.</dt><dd><p class="no_top_margin">Dornase alfa</p></dd><dt>4.</dt><dd><p class="no_top_margin">Airway clearance</p></dd><dt>5.</dt><dd><p class="no_top_margin">Inhaled corticosteroids and/or long-acting beta agonist (for select individuals)</p></dd><dt>6.</dt><dd><p class="no_top_margin">Aerosolized antibiotic</p></dd></dl><div class="half_rhythm">The rationale for this sequence is to open the airway, decrease sputum viscosity, promote expectoration of secretions, and then deliver anti-inflammatory treatments and/or antibiotics as widely and deeply as possible within the bronchial tree.</div></li><li class="half_rhythm"><div class="half_rhythm">Aggressive antibiotic treatment at the time of initial isolation of <i>P. aeruginosa</i> from cultured airway secretions helps prevent chronic airway infection.</div></li><li class="half_rhythm"><div class="half_rhythm">All routine immunizations should be given at the recommended times. Especially important are vaccines that protect against microorganisms associated with pulmonary manifestations, including pertussis, measles, varicella, <i>Haemophilus influenzae</i> type B, and <i>Streptococcus pneumoniae</i>.</div></li><li class="half_rhythm"><div class="half_rhythm">Influenza vaccine should be administered annually in infants age six months and older. Note: (1) Because the influenza vaccine may not be fully protective, consider immunizing an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's entire family. (2) CF individuals with suspected influenza should receive anti-viral medications targeted toward influenza A and B.</div></li><li class="half_rhythm"><div class="half_rhythm">Anti-RSV monoclonal antibody (Synagis<sup>&#x000ae;</sup>) should be considered for infants up to age 12 months for the duration of the local RSV season, particularly in individuals with ongoing pulmonary symptoms.</div></li><li class="half_rhythm"><div class="half_rhythm">Physical activity, exercise, and conditioning help maintain bone health and improve airway clearance.</div></li></ul><p><b>Exocrine pancreatic insufficiency</b></p><ul><li class="half_rhythm"><div>Pancreatic enzyme replacement and supplementation of fat-soluble vitamins</div></li><li class="half_rhythm"><div>High-calorie, high-fat nutritional supplements</div></li><li class="half_rhythm"><div>Consultation with a nutritionist specializing in CF</div></li><li class="half_rhythm"><div>Extra salt and water for hydration and salt losses in hot, dry climates</div></li></ul></div><div id="cf.Surveillance__Cystic_Fibrosis"><h3>Surveillance &#x02013; Cystic Fibrosis</h3><p><b>Respiratory</b></p><ul><li class="half_rhythm"><div>Newborns are examined monthly by a CF care provider for the first six months of life and then bimonthly until age one year.</div></li><li class="half_rhythm"><div>Individuals age one year and older should be examined quarterly by a CF care provider to monitor for subtle changes in physical examination that are not yet manifest as symptoms.</div></li><li class="half_rhythm"><div>Culture respiratory tract secretions at least four times yearly. Some individuals may benefit from more frequent visits and respiratory tract surveillance cultures (see <a href="#cf.Therapies_Under_Investigation">Therapies Under Investigation</a>).</div></li><li class="half_rhythm"><div>Pulmonary function studies, chest radiographic examination, and at least annual blood tests for electrolytes, fat soluble vitamin levels, and IgE levels are appropriate.</div></li><li class="half_rhythm"><div>Bronchoscopy and chest CT examination are indicated for individuals with symptoms and signs of lung disease who fail to respond to intervention.</div></li></ul><p><b>Exocrine pancreatic insufficiency</b></p><ul><li class="half_rhythm"><div>Weight gain and caloric intake are monitored monthly in newborns until age six months.</div></li><li class="half_rhythm"><div>Fecal elastase may need to be repeated during the first year of life, particularly if infants have signs or symptoms of malabsorption or inadequate weight gain.</div></li><li class="half_rhythm"><div>Measure oral glucose tolerance annually after age ten years during a period of stable health. Plasma glucose is measured fasting and two hours after an oral glucose load of 1.75 g/kg, or 75 g maximum.</div></li><li class="half_rhythm"><div>Evaluate bone mineral density in adolescence.</div></li></ul><p><b>Liver disease.</b> Annual screening of liver function tests and liver ultrasound to monitor progression of liver disease is appropriate.</p></div><div id="cf.AgentsCircumstances_to_Avoid__Cystic"><h3>Agents/Circumstances to Avoid &#x02013; Cystic Fibrosis</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Respiratory irritants (e.g., smoke, dust)</div></li><li class="half_rhythm"><div>Individuals with respiratory infections</div></li><li class="half_rhythm"><div>Dehydration; add extra salt and water to diet in hot, dry climates because of perspiration-related salt losses (see <a href="#cf.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</a>).</div></li></ul></div><div id="cf.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate apparently asymptomatic older and younger sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>/at-risk relatives in order to identify as early as possible those who should be referred to a cystic fibrosis center for initiation of treatment and preventive measures.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the pathogenic variants in the family are known;</div></li><li class="half_rhythm"><div>Sweat chloride testing if the pathogenic variants in the family are not known.</div></li></ul><p>See <a href="#cf.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="cf.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancies are well tolerated with improved nutrition, improved pulmonary treatment, aggressive management of infections, and a multidisciplinary care team, especially in women with mild to moderate disease. Pregnancy is not associated with an increased risk of death [<a class="bk_pop" href="#cf.REF.goss.2003.1460">Goss et al 2003</a>]. In all studies published to date, the most important predictors of pregnancy outcome are the severity of maternal pulmonary impairment and nutritional status; deterioration during pregnancy may precipitate preterm delivery.</p><ul><li class="half_rhythm"><div>Females with CF of reproductive age should receive preconception counseling and take steps to optimize health prior to pregnancy.</div></li><li class="half_rhythm"><div>The management of pregnancy and the immediate postpartum period for a woman with CF requires a dietician, members of the CF team, and a maternal fetal medicine specialist.</div></li><li class="half_rhythm"><div>Maternal nutritional status and weight gain should be monitored and optimized aggressively and pulmonary exacerbations should be treated early.</div></li><li class="half_rhythm"><div>Traditional screening paradigms for gestational diabetes mellitus may not be useful in pregnancies of women with CF; therefore, screening at each trimester of pregnancy has been suggested to improve the detection of diabetes mellitus.</div></li><li class="half_rhythm"><div>As in pregnancies of women with other forms of diabetes mellitus, fetal outcome is optimized when glycemic control is achieved prior to pregnancy.</div></li><li class="half_rhythm"><div>Mode of delivery is based on usual obstetric indications.</div></li></ul></div><div id="cf.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Ursodeoxycholic acid may be cytoprotective and increase bile flow to improve hepatic enzyme levels, bile drainage, liver histology, and nutritional status [<a class="bk_pop" href="#cf.REF.desmond.2007.1402">Desmond et al 2007</a>, <a class="bk_pop" href="#cf.REF.cheng.2012.cd000222">Cheng et al 2012</a>, <a class="bk_pop" href="#cf.REF.leeuwen.2014.69">Leeuwen et al 2014</a>]. However, whether ursodiol therapy can prevent progression of liver disease in the subset of individuals with CF who are at risk for this complication is uncertain [<a class="bk_pop" href="#cf.REF.brigman.2006.484">Brigman &#x00026; Feranchak 2006</a>, <a class="bk_pop" href="#cf.REF.leeuwen.2014.69">Leeuwen et al 2014</a>].</p><p><i>CFTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>-specific candidate drugs:</p><ul><li class="half_rhythm"><div>CF correctors such as VX-661 are small-molecule therapies being developed to increase the quantity of functional CFTR protein at the cell surface in individuals with specific <i>CFTR</i> pathogenic variants (including the most common CF variant, p.Phe508del).</div></li><li class="half_rhythm"><div>Inhaled dry powder mannitol has demonstrated relative sustained improvement in lung function in both European and American trials [<a class="bk_pop" href="#cf.REF.bilton.2011.1071">Bilton at al 2011</a>, <a class="bk_pop" href="#cf.REF.aiken.2012.2308">Aiken et al 2012</a>].</div></li><li class="half_rhythm"><div>Alternate ion channel regulation is being investigated as a strategy to restore airway surface liquid.</div></li></ul><p><b>Gene therapy.</b> Gene therapy is in early clinical trials. Gene therapy is not able to control or treat the symptoms related to CF at this time [<a class="bk_pop" href="#cf.REF.prickett.2013.255">Prickett &#x00026; Jain 2013</a>]</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> for access to information on clinical studies for a wide range of diseases and conditions.</p></div><div id="cf.Other"><h3>Other</h3><p>While there has been much interest in developing active and passive immunization strategies against <i>Pseudomonas aeruginosa</i>, an effective vaccine against <i>P. aeruginosa</i> has not yet been developed.</p></div></div><div id="cf.Genetic_Counseling"><h2 id="_cf_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="cf.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Cystic fibrosis (CF) and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> absence of the vas deferens (CAVD) are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="cf.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with CF</b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>CFTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are generally asymptomatic.</div></li><li class="half_rhythm"><div>On rare occasions, a parent may be diagnosed as <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> subsequent to the diagnosis of the child.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with CF</b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are generally asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with CF</b></p><ul><li class="half_rhythm"><div>Females with CF can be fertile.</div></li><li class="half_rhythm"><div>Males with CF may conceive children through assisted reproductive technologies (ART).</div></li><li class="half_rhythm"><div>Offspring of a male or female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with CF inherit one <i>CFTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from their <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>The risk that a child will inherit a second <i>CFTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> depends on the reproductive partner's genetic status. If the reproductive partner is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>CFTR</i> pathogenic variant, offspring are at a 50% risk of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and a 50% risk of being obligate heterozygotes.</div></li></ul><p><b>Parents, sibs, and offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with CAVD</b></p><ul><li class="half_rhythm"><div>Males with CAVD may conceive children through assisted reproductive technologies (ART).</div></li><li class="half_rhythm"><div>The risk to the relatives of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with CAVD depends on the parental genotypes and cannot readily be predicted without this information.</div></li><li class="half_rhythm"><div>Molecular genetic testing is most informative when the CAVD-causing <i>CFTR</i> variants have been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>. Men with CAVD may have only one identifiable <i>CFTR</i> variant, complicating the testing and interpretation of results in their family members.</div></li></ul><p><b>Other family members.</b> Each sib of an individual known to be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>CFTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="cf.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>CFTR</i> pathogenic variants in the family.</p><p>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is deceased and molecular testing was not performed, it is appropriate to attempt to obtain an available tissue sample for <i>CFTR</i> molecular testing. If molecular testing cannot be done on the proband's tissue, it is appropriate to offer molecular testing to at-risk family members. Individuals in whom a <i>CFTR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is not identified have a reduced <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> risk (see <a class="figpopup" href="/books/NBK1250/table/cf.T.residual_risk_of_being_a_carrier_fo/?report=objectonly" target="object" rid-figpopup="figcfTresidualriskofbeingacarrierfo" rid-ob="figobcfTresidualriskofbeingacarrierfo">Table 4</a>).</p><p>5T and TG tract typing should not be included in a routine <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> screen. The 5T/TG tract analysis is not able to provide a specific risk figure for developing symptoms or having a child who develops symptoms of non-classic CF or CAVD; it is able to assign risk as "increased" or "decreased."</p><p>If an individual has the p.Arg117His <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, reflex testing for the variants 5T/7T/9T is recommended. If the individual has the 5T <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, family studies are recommended to determine if the 5T allele is in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration or <a class="def" href="/books/n/gene/glossary/def-item/trans/"><i>trans</i></a> configuration with the p.Arg117His allele. An individual with p.Phe508del and 5T/11TG is highly unlikely to develop non-classic CF. An individual with p.Phe508del and 5T/12TG or p.Phe508del and 5T/13TG may rarely develop CAVD or non-classic CF [<a class="bk_pop" href="#cf.REF.groman.2004.176">Groman et al 2004</a>].</p><p>Multiple naming systems are still in use for <i>CFTR</i> pathogenic variants. When ordering targeted testing for <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <i>CFTR</i> variants, it is important to know whether a particular variant is named using the legacy or HGVS convention (see <a class="bk_pop" href="#cf.REF.berwouts.2011.1197">Berwouts et al [2011]</a> for review).</p><div id="cf.T.residual_risk_of_being_a_carrier_fo" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Residual Risk of Being a Carrier for a <i>CFTR</i> Pathogenic Variant if Molecular Testing Does Not Detect a Pathogenic Variant</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1250/table/cf.T.residual_risk_of_being_a_carrier_fo/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cf.T.residual_risk_of_being_a_carrier_fo_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_1" style="text-align:left;vertical-align:middle;">Prior Risk of<br />Being a Carrier</th><th id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" colspan="10" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Residual Risk (%) of Being a Carrier if the Pathogenic Variant Detection Rate Is:</th></tr><tr><th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">30%</th><th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40%</th><th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</th><th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%</th><th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%</th><th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">75%</th><th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%</th><th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_8" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">85%</th><th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_9" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">90%</th><th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_10" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%</th></tr></thead><tbody><tr><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>2/3</b></td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">58.3%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">54.5%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50.0%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">44.4%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">37.5%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">33.3%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">28.6%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23.1%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16.7%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7.4%</td></tr><tr><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>1/2</b></td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">41.2%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">37.5%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">33.3%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">28.6%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23.1%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20.0%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16.7%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13.0%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9.1%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3.8%</td></tr><tr><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>1/4</b></td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">18.9%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16.7%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14.3%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11.8%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9.1%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7.7%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6.3%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4.8%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3.2%</td><td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.3%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">See <a href="/books/NBK1250/bin/cf-Table4a.pdf">Table 4a</a> (pdf) for residual risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> for other values of prior risk.</p></div></dd></dl></div></div></div></div><div id="cf.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#cf.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on testing at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a>, potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="cf.Population_Screening"><h3>Population Screening</h3><p>Screening for CF <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status is offered to some couples as part of routine prenatal care. The ACMG Subcommittee on Cystic Fibrosis Screening recommends offering CF carrier screening to individuals of northern European background and Ashkenazi Jews, and making carrier screening available to other ethnic groups. The Subcommittee recommends a pan ethnic panel including 23 pathogenic variants that includes the majority of CF-causing pathogenic variants with an <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> of greater than 0.1% in the general US population (<a class="figpopup" href="/books/NBK1250/table/cf.T.recommended_panel_of_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figcfTrecommendedpanelofpathogenicvar" rid-ob="figobcfTrecommendedpanelofpathogenicvar">Table 6</a>) [<a class="bk_pop" href="#cf.REF.grody.2001">Grody et al 2001</a>] (<a href="http://www.nature.com/gim/journal/v3/n2/full/gim200129a.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><p>The <a href="http://link.springer.com/article/10.1007/s10897-013-9636-9/fulltext.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NSGC Practice Guideline</a> recommends that <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for CF be offered to all women of reproductive age, regardless of ancestry; preferably before conception. Pan ethnic panels that include pathogenic variants more commonly identified in minority populations are appropriate to consider for individuals of non-northern European descent. See <a href="#cf.Carrier_Heterozygote_Detection">Carrier Detection</a> for information on interpretation of results of CF carrier testing.</p><p>Individuals with no family history of CF and negative <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> have a reduced carrier risk. <a class="figpopup" href="/books/NBK1250/table/cf.T.residual_risk_to_an_individual_with/?report=objectonly" target="object" rid-figpopup="figcfTresidualrisktoanindividualwith" rid-ob="figobcfTresidualrisktoanindividualwith">Table 5</a> provides calculations of the residual risk of being a carrier based on the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> detection rate of the test method used and the individual's a priori risk of being a carrier. The laboratory should be provided with complete and accurate information regarding the patient's ethnicity and family history of CF to facilitate accurate calculation of residual risk.</p><div id="cf.T.residual_risk_to_an_individual_with" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Residual Risk to an Individual with No Family History of a <i>CFTR</i>-Related Disorder of Being a Carrier (Heterozygote) if Molecular Genetic Testing Does Not Detect a Pathogenic Variant</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1250/table/cf.T.residual_risk_to_an_individual_with/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cf.T.residual_risk_to_an_individual_with_lrgtbl__"><table><thead><tr><th id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_1" style="text-align:left;vertical-align:middle;">Prior Risk of<br />Being a Carrier</th><th id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" colspan="10" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Residual Risk (%) of Being a Carrier if the Pathogenic Variant Detection Rate Is:</th></tr><tr><th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">30%</th><th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40%</th><th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</th><th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%</th><th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%</th><th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">75%</th><th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%</th><th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_8" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">85%</th><th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_9" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">90%</th><th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_10" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%</th></tr></thead><tbody><tr><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>1/28 (3.57%)</b></td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.5%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.2%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.8%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.5%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.1%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.9%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.7%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.6%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.4%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.15%</td></tr><tr><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>1/60 (1.7%)</b></td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.2%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.0%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.8%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.7%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.5%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.4%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.3%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.3%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.2%</td><td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.06%</td></tr></tbody></table></div></div><p><b>For more information,</b> see the American College of Medical Genetics Carrier Screening ACT Sheets <a href="http://www.acmg.net/PDFLibrary/CF-Mutation-not-R117H.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">C<i>FTR</i> Mutations except R117H</a>, <a href="http://www.acmg.net/PDFLibrary/CF-Mutation-R117H.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cystic Fibrosis R117H</a>, and <a href="http://www.acmg.net/PDFLibrary/CF-No-Mutation.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">No Mutations Detected by Carrier Screening</a>.</p></div><div id="cf.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>High-risk pregnancies.</b> Once the <i>CFTR</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for CF are possible.</p><p><b>Indeterminate-risk pregnancies.</b> Amniotic fluid digestive enzyme analysis may be helpful for <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> in pregnancies of indeterminate risk following <i>CFTR</i> analysis [<a class="bk_pop" href="#cf.REF.oca.2009.2214">Oca et al 2009</a>].</p><p><b>Low-risk pregnancies.</b> The finding of fetal echogenic bowel and/or dilated bowel on ultrasound examination is associated with an increased risk for CF in a pregnancy previously not known to be at increased risk for CF. <a class="bk_pop" href="#cf.REF.scotet.2010.592.e1">Scotet et al [2010]</a> found a 6.7% incidence of CF in 289 fetuses with the <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of Grade 3 echogenic bowel, defined as echogenicity similar to or greater than that of surrounding fetal bone and/or intestinal dilation. In this situation, <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> of the parents regarding the risk for CF is appropriate, followed by <i>CFTR</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the parents and/or the fetus, depending on the gestational age of the pregnancy and the decision of the parents. Based on the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> detection rate of the test method used, the risk for CF when only one pathogenic variant is identified in the fetus can be calculated [<a class="bk_pop" href="#cf.REF.bosco.1999.1020">Bosco et al 1999</a>, <a class="bk_pop" href="#cf.REF.hodge.1999.329">Hodge et al 1999</a>].</p></div></div><div id="cf.Resources"><h2 id="_cf_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Cystic Fibrosis Canada</b></div><div>Canada</div><div><b>Phone:</b> 800-378-2233</div><div><a href="http://www.cysticfibrosis.ca/?lang=en" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cysticfibrosis.ca</a></div></li><li class="half_rhythm"><div><b>Cystic Fibrosis Foundation</b></div><div>6931 Arlington Road</div><div>2nd Floor</div><div>Bethesda MD 20814</div><div><b>Phone:</b> 800-344-4823 (toll-free); 301-951-4422</div><div><b>Fax:</b> 301-951-6378</div><div><b>Email:</b> info@cff.org</div><div><a href="http://www.cff.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cff.org</a></div></li><li class="half_rhythm"><div><b>Genetic Disorders of Mucociliary Clearance Consortium (GDMCC)</b></div><div>Cystic Fibrosis / Pulmonary Research &#x00026; Treatment Center</div><div>Marsico Lung Institute</div><div>7215 Marsico Hall</div><div>CB #7248</div><div>Chapel Hill NC 27599-7248</div><div><b>Fax:</b> 919-966-7524; 919-843-5309</div><div><b>Email:</b> godwine@med.unc.edu; kelli_sullivan@med.unc.edu</div><div><a href="https://www.rarediseasesnetwork.org/cms/gdmcc" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Genetic Diseases Of Mucociliary Clearance Consortium</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/cysticfibrosis.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cystic Fibrosis</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Cystic%20fibrosis&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cystic fibrosis</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22202/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cystic fibrosis</a></div></li><li class="half_rhythm"><div><b>Save Babies Through Screening Foundation, Inc.</b></div><div>P. O. Box 42197</div><div>Cincinnati OH 45242</div><div><b>Phone:</b> 888-454-3383</div><div><b>Email:</b> email@savebabies.org</div><div><a href="http://www.savebabies.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.savebabies.org</a></div></li><li class="half_rhythm"><div><b>Medical Home Portal</b></div><div><i>The Parents &#x00026; Families section of the Medical Home Portal provides information and resources to help families learn how to better care for a child with chronic and complex conditions and to become more effective partners in their child&#x02019;s care.</i></div><div>Department of Pediatrics University of Utah</div><div>P.O. Box 581289</div><div>Salt Lake City UT 84158</div><div><b>Phone:</b> 801-213-3920</div><div><b>Email:</b> info@medicalhomeportal.org</div><div><a href="https://www.medicalhomeportal.org/living-with-child" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">For Parents &#x00026; Families</a></div></li><li class="half_rhythm"><div><b>Cystic Fibrosis Foundation Patient Registry Report</b></div><div>6931 Arlington Road</div><div>2nd Floor</div><div>Bethesda MD 20814</div><div><b>Phone:</b> 800-344-4823 (toll-free); 301-951-4422</div><div><b>Fax:</b> 301-951-6378</div><div><b>Email:</b> info@cff.org</div><div><a href="http://www.cff.org/research/ClinicalResearch/PatientRegistryReport" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CF Foundation Patient Registry</a></div></li><li class="half_rhythm"><div><b>European Cystic Fibrosis Society Patient Registry</b></div><div><b>Email:</b> helpdesk@ecfregistry.eu</div><div><a href="https://www.ecfs.eu/projects/ecfs-patient-registry/contact" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ecfs.eu/projects/ecfs-patient-registry/contact</a></div></li></ul></div><div id="cf.Molecular_Genetics"><h2 id="_cf_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="cf.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Cystic Fibrosis and Congenital Absence of the Vas Deferens: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1250/table/cf.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cf.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_cf.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_cf.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_cf.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_cf.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_cf.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_cf.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_cf.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1080" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CFTR</i></a></td><td headers="hd_b_cf.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1080" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7q31<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_cf.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P13569" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cystic fibrosis transmembrane conductance regulator</a></td><td headers="hd_b_cf.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://cftr2.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFTR2</a><br /><a href="http://www.genet.sickkids.on.ca/cftr/app" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cystic Fibrosis Mutation Database</a><br /><a href="https://databases.lovd.nl/shared/genes/CFTR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Locus Specific Mutation Database Directory</a></td><td headers="hd_b_cf.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CFTR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFTR</a></td><td headers="hd_b_cf.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CFTR[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFTR</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="cf.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="cf.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Cystic Fibrosis and Congenital Absence of the Vas Deferens (<a href="/omim/219700,277180,602421" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1250/table/cf.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cf.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/219700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">219700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CYSTIC FIBROSIS; CF</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/277180" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">277180</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VAS DEFERENS, CONGENITAL BILATERAL APLASIA OF; CBAVD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602421" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602421</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>CFTR</i> is 230 kb long and contains 27 coding exons. It produces a 6.5-kb <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> product.</p><p><b>Pathogenic variants.</b> More than 1,000 <i>CFTR</i> variants have been reported. Almost all are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants or small (1-84 bp) deletions. The most common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is p.Phe508del, accounting for an estimated 30%-80% (depending on the ethnic group) of pathogenic variants. <a class="figpopup" href="/books/NBK1250/table/cf.T.recommended_panel_of_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figcfTrecommendedpanelofpathogenicvar" rid-ob="figobcfTrecommendedpanelofpathogenicvar">Table 6</a> lists the panel of 23 alleles recommended by the American College of Medical Genetics for routine diagnostic and <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> [<a class="bk_pop" href="#cf.REF.watson.2004.387">Watson et al 2004</a>]. <a class="figpopup" href="/books/NBK1250/table/cf.T.ten_most_common_cftr_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figcfTtenmostcommoncftrpathogenicvar" rid-ob="figobcfTtenmostcommoncftrpathogenicvar">Table 7</a> lists ten of the most common <i>CFTR</i> pathogenic variants. The Clinical and Functional Translation of CFTR (CFTR2) website provides information about whether a pathogenic variant causes CF when combined with another CF-causing pathogenic variant and about the sweat chloride, lung function, pancreatic status, and pseudomonas infection rates in individuals in the CFTR2 database with specific pathogenic variants. Information on the CFTR2 website is updated as further analysis is completed (<a href="http://www.cftr2.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cftr2.org</a>).</p><p>Not all reported <i>CFTR</i> pathogenic variants are proven by population or functional studies to be pathogenic or CF-causing. The disease liability of <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants is particularly difficult to determine from case reports [<a class="bk_pop" href="#cf.REF.sosnay.2013.1160">Sosnay et al 2013</a>].</p><p>Resources for information about <i>CFTR</i> variants include the following:</p><ul><li class="half_rhythm"><div><a href="http://www.sickkids.ca/search/search.aspx?SearchTerm=cftr1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sick Kids</a></div></li><li class="half_rhythm"><div><a href="https://www.cftr2.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CFTR2</a></div></li><li class="half_rhythm"><div><a href="http://www.umd.be/CFTR/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UMD-<i>CFTR</i> Knowledgebase</a></div></li><li class="half_rhythm"><div><a href="https://www.ncbi.nlm.nih.gov/clinvar/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinVar-NCBI</a></div></li></ul><div id="cf.T.recommended_panel_of_pathogenic_var" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Recommended Panel of Pathogenic Variants for General Population CF Carrier Screening</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1250/table/cf.T.recommended_panel_of_pathogenic_var/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cf.T.recommended_panel_of_pathogenic_var_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(---&#x000a0;<sup>1</sup>)</th><th id="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(---&#x000a0;<sup>1</sup>)</th><th id="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequence</th></tr></thead><tbody><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.254G&#x0003e;A</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly85Glu<br />(G85E)</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_3" rowspan="24" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000492.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000492<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.350G&#x0003e;A</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg117H<br />(R117H)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1000C&#x0003e;T</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg334Typ<br />(R334W)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1040G&#x0003e;C</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg347Pro<br />(R347P)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1364C&#x0003e;A</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala455Glu<br />(A455E)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1624G&#x0003e;T</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly542Ter<br />(G542X)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1652G&#x0003e;A</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly551Asp<br />(G551D)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1657C&#x0003e;T</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg553Ter<br />(R553X)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1679G&#x0003e;C</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg560Thr<br />(R560T)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3484C&#x0003e;T</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1162Ter<br />(R1162X)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3846G&#x0003e;A</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp1282Ter<br />(W1282X)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3909C&#x0003e;G</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn1303Lys<br />(N1303K)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.489+1G&#x0003e;T<br />(621+1G&#x0003e;T)</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.579+1G&#x0003e;T<br />(711+1G&#x0003e;T)</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1519_1521delATC</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile507del<br />(&#x00394;I507)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1521_1523delCTT</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe508del<br />(&#x00394;F508)</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1585-1G&#x0003e;A<br />(1717-1&#x0003e;A)</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1766+1G&#x0003e;A<br />(1898+1G&#x0003e;A)</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2052delA<br />(2184delA)</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2657+5G&#x0003e;A<br />(2789+5G&#x0003e;A)</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2988+1G&#x0003e;A<br />(3120+1G&#x0003e;A)</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3527delC<br />(3659delC)</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3718-2477C&#x0003e;T<br />(3849+10kbC&#x0003e;T)</td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1210-12T[5_9]<br />(5T/7T/9T)&#x000a0;<sup>2</sup></td><td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="cf.TF.6.1"><p class="no_margin">Legacy nomenclature</p></div></dd><dt>2. </dt><dd><div id="cf.TF.6.2"><p class="no_margin">Recommended as a reflex test when p.Arg117His is detected</p></div></dd></dl></div></div></div><div id="cf.T.ten_most_common_cftr_pathogenic_var" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Ten Most Common <i>CFTR</i> Pathogenic Variants in Individuals of Northern European Background</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1250/table/cf.T.ten_most_common_cftr_pathogenic_var/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cf.T.ten_most_common_cftr_pathogenic_var_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pathogenic Variant</th><th id="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Relative Frequency</th><th id="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pathogenic Variant Functional Class&#x000a0;<sup>1,&#x000a0;2</sup></th></tr></thead><tbody><tr><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe508del</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">66.0%</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">II</td></tr><tr><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly542Ter</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.4%</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">I</td></tr><tr><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly551Asp</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.6%</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">III</td></tr><tr><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn1303Lys</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.3%</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">II</td></tr><tr><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Typ1282Ter</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.2%</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">I</td></tr><tr><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg553Ter</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.7%</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">I</td></tr><tr><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.489+1G&#x0003e;T</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.7%</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">I</td></tr><tr><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1585-1G&#x0003e;A</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.6%</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">I</td></tr><tr><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg117His</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.3%</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">IV</td></tr><tr><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1162Ter</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.3%</td><td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not clear&#x000a0;<sup>3</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Based on <a href="http://www.genet.sickkids.on.ca/cftr/app" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cystic Fibrosis Mutation Database</a> and <a class="bk_pop" href="#cf.REF.mckone.2003.1671">McKone et al [2003]</a></p></div></dd><dt>1. </dt><dd><div id="cf.TF.7.1"><p class="no_margin">For information on phenotypic expression and functional studies, see <a href="http://www.cftr2.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www<wbr style="display:inline-block"></wbr>​.cftr2.org</a>.</p></div></dd><dt>2. </dt><dd><div id="cf.TF.7.2"><p class="no_margin">See <a class="figpopup" href="/books/NBK1250/table/cf.T.historical_classification_scheme_fo/?report=objectonly" target="object" rid-figpopup="figcfThistoricalclassificationschemefo" rid-ob="figobcfThistoricalclassificationschemefo">Table 8</a>.</p></div></dd><dt>3. </dt><dd><div id="cf.TF.7.3"><p class="no_margin">Transcript is stable; truncated protein is probably misfolded; therefore, likely Class II.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Cystic fibrosis transmembrane conductance regulator (<i>CFTR</i>) is a 1,480-amino-acid integral membrane protein that functions as a regulated chloride channel in epithelia.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants can affect the CFTR protein quantitatively, qualitatively, or both. <a class="figpopup" href="/books/NBK1250/table/cf.T.historical_classification_scheme_fo/?report=objectonly" target="object" rid-figpopup="figcfThistoricalclassificationschemefo" rid-ob="figobcfThistoricalclassificationschemefo">Table 8</a> illustrates the historical classification scheme for the functional consequences of <i>CFTR</i> pathogenic variants. Several pathogenic variants actually cross several categories in their effects. Recently, with the advent of molecular-based treatments (see <a href="#cf.Therapies_Under_Investigation">Therapies Under Investigation</a>), the necessary classification categories have been reduced to two: reduced production and reduced function [<a class="bk_pop" href="#cf.REF.cutting.2015.45">Cutting 2015</a>].</p><div id="cf.T.historical_classification_scheme_fo" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p>Historical Classification Scheme for <i>CFTR</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1250/table/cf.T.historical_classification_scheme_fo/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cf.T.historical_classification_scheme_fo_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pathogenic<br />Variant<br />Class</th><th id="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Effect of Pathogenic Variant on CFTR Protein&#x000a0;<sup>1</sup></th><th id="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mechanisms</th></tr></thead><tbody><tr><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">I</td><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reduced or absent synthesis</td><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nonsense, frameshift, or splice junction variants</td></tr><tr><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">II</td><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Block in protein processing</td><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Missense variants, amino acid deletions</td></tr><tr><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">III</td><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Block in regulation of CFTR chloride channel</td><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Missense variants</td></tr><tr><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">IV</td><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Altered conductance of CFTR chloride channel</td><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Missense variants</td></tr><tr><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">V</td><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reduced synthesis/trafficking</td><td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Missense, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Based on <a class="bk_pop" href="#cf.REF.wilschanski.1995.705">Wilschanski et al [1995]</a>, <a class="bk_pop" href="#cf.REF.zielenski.1995.777">Zielenski &#x00026; Tsui [1995]</a> (Figure 3), <a class="bk_pop" href="#cf.REF.welsh.2001">Welsh et al [2001]</a>, <a class="bk_pop" href="#cf.REF.cutting.2015.45">Cutting [2015]</a></p></div></dd><dt>1. </dt><dd><div id="cf.TF.8.1"><p class="no_margin">There are numerous exceptions to <i>CFTR</i> <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> (e.g., Ala455Glu is Class II but associated with mild lung disease and pancreatic sufficiency).</p></div></dd></dl></div></div></div><div id="cf.Genetic_Modifiers_of_CF_Phenotype"><h3>Genetic Modifiers of CF Phenotype</h3><p><b><i>CFTR</i>, 5T/TG tract analysis.</b> A poly T tract, a string of thymidine bases located in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 8 of <i>CFTR</i>, can be associated with <i>CFTR</i>-related disorders depending on its size. The three common variants of the poly T tract are 5T, 7T, and 9T. Both 7T and 9T are considered polymorphic variants and 5T is considered a variably penetrant variant. The 5T variant is thought to decrease the efficiency of intron 8 <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>. Poly T testing is appropriate as a reflex test when an Arg117His variant is detected or an adult male is being evaluated for CAVD (see <a href="#cf.Related_Genetic_Counseling_Issues">Related Genetic Counseling Issues</a>).</p><p>A TG tract lies just 5' of the poly T tract. It consists of a short string of TG repeats that commonly number 11, 12, or 13. A longer TG tract (12 or 13) in conjunction with a shorter poly T tract (5T) has the strongest adverse effect on proper <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 8 <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> [<a class="bk_pop" href="#cf.REF.cuppens.1998.487">Cuppens et al 1998</a>, <a class="bk_pop" href="#cf.REF.groman.2004.176">Groman et al 2004</a>, <a class="bk_pop" href="#cf.REF.sun.2006.339">Sun et al 2006</a>].</p><p>There are ongoing investigations of genetic modifiers of CF nutritional status, liver disease, diabetes, and lung disease. Heritability of several of these traits is high, indicating a significant role for non-<i>CFTR</i> genetic modifiers [<a class="bk_pop" href="#cf.REF.knowles.2012.a009548">Knowles &#x00026; Drumm 2012</a>]. To date, the association of several genes has been replicated in multiple studies:</p><ul><li class="half_rhythm"><div><i>MBL2</i>, <i>EDNRA</i>, and <i>TGF-&#x003b2;1</i> in lung function</div></li><li class="half_rhythm"><div><i>MBL2</i> in age at first <i>P. aeruginosa</i> infection</div></li><li class="half_rhythm"><div><i>MSRA</i> in meconium ileus</div></li><li class="half_rhythm"><div><i>TCF7L2</i> in CF-related diabetes [<a class="bk_pop" href="#cf.REF.knowles.2012.a009548">Knowles &#x00026; Drumm 2012</a>]</div></li><li class="half_rhythm"><div><i>SERPINA1</i> in CF-related liver disease [<a class="bk_pop" href="#cf.REF.bartlett.2009.1076">Bartlett et al 2009</a>]</div></li></ul><p>While these genes/variants may be targeted for future therapeutic interventions, no genetic modifier is well established enough at the time of this update to offer clinical testing or change clinical management based on non-<i>CFTR</i> <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>.</p></div></div><div id="cf.References"><h2 id="_cf_References_">References</h2><div id="cf.Published_GuidelinesConsensus_Stateme"><h3>Published Guidelines/Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="cf.REF.grody.2001">Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ (Subcommittee on Cystic Fibrosis Screening, Accreditation of Genetic Services Committee, ACMG). Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Available <a href="http://www.nature.com/gim/journal/v3/n2/full/gim200129a.html" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2001. Accessed 7-26-18. [<a href="/pubmed/11280952" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11280952</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.langfelderschwind.2014">Langfelder-Schwind E, Karczeski B, Strecker MN, Redman J, Sugarman EA, Zaleski C, Brown T, Keiles S, Powers A, Ghate S, Darrah R. Molecular Testing for Cystic Fibrosis Carrier Status Practice Guidelines: Recommendations of the National Society of Genetic Counselors. Available <a href="http://link.springer.com/article/10.1007/s10897-013-9636-9/fulltext.html" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2014. Accessed 7-26-18. [<a href="/pubmed/24014130" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24014130</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF3">National Institutes of Health. Consensus statement on genetic testing for cystic fibrosis. Available <a href="https://consensus.nih.gov/1997/1997GeneticTestCysticFibrosis106html.htm" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 1997. Accessed 7-26-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.wilson.2002.644">Wilson RD, Davies G, Desilets V, Reid GJ, Shaw D, Summers A, Wyatt P, Young D, Crane J, Armson A, de la Ronde S, Farine D, Leduc L, Van Aerde J., Society of Obstetricians and Gynaecologists of Canada.  Cystic fibrosis carrier testing in pregnancy in Canada. <span><span class="ref-journal">J Obstet Gynaecol Can. </span>2002;<span class="ref-vol">24</span>:644–51.</span> [<a href="/pubmed/12196844" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12196844</span></a>]</div></li></ul></div><div id="cf.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="cf.REF.aiken.2012.2308">Aiken ML, Painter RG, Zhou Y, Wang G. Chloride transport in functionally active phagosomes isolated from Human neutrophils. <span><span class="ref-journal">Free Radic Biol Med. </span>2012;<span class="ref-vol">53</span>:2308–17.</span> [<a href="/pmc/articles/PMC3672382/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3672382</span></a>] [<a href="/pubmed/23089227" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23089227</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.bartlett.2009.1076">Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemkov&#x000e1; D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR, et al.  Genetic modifiers of liver disease in cystic fibrosis. <span><span class="ref-journal">JAMA. </span>2009;<span class="ref-vol">302</span>:1076–83.</span> [<a href="/pmc/articles/PMC3711243/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3711243</span></a>] [<a href="/pubmed/19738092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19738092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.berwouts.2011.1197">Berwouts S, Morris MA, Girodon E, Schwarz M, Stuhrmann M, Dequeker E. Mutation nomenclature in practice: findings and recommendations from the cystic fibrosis external quality assessment scheme. <span><span class="ref-journal">Hum Mutat. </span>2011;<span class="ref-vol">32</span>:1197–203.</span> [<a href="/pubmed/21796730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21796730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.bilton.2011.1071">Bilton D, Robinson P, Cooper P, Gallagher CG, Kolbe J, Fox H, Jaques A, Charlton B. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. <span><span class="ref-journal">Eur Respir J. </span>2011;<span class="ref-vol">38</span>:1071–80.</span> [<a href="/pubmed/21478216" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21478216</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.bombieri.2011.s86">Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, Castellani C, Cuppens H, Cutting GR, Drev&#x000ed;nek P, Farrell P, Elborn JS, Jarvi K, Kerem B, Kerem E, Knowles M, Macek M Jr, Munck A, Radojkovic D, Seia M, Sheppard DN, Southern KW, Stuhrmann M, Tullis E, Zielenski J, Pignatti PF, Ferec C. Recommendations for the classification of diseases as CFTR-related disorders. <span><span class="ref-journal">J Cyst Fibros. </span>2011;<span class="ref-vol">10</span> Suppl 2:S86–102.</span> [<a href="/pubmed/21658649" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21658649</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.borowitz.2009.s106">Borowitz D, Parad RB, Sharp JK, Sabadosa KA, Robinson KA, Rock MJ, Farrell PM, Sontag MK, Rosenfeld M, Davis SD, Marshall BC, Accurso FJ. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. <span><span class="ref-journal">J Pediatr. </span>2009;<span class="ref-vol">155</span>:S106–16.</span> [<a href="/pmc/articles/PMC6326077/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6326077</span></a>] [<a href="/pubmed/19914443" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19914443</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.bosco.1999.1020">Bosco AF, Norton ME, Lieberman E. Predicting the risk of cystic fibrosis with echogenic fetal bowel and one cystic fibrosis mutation. <span><span class="ref-journal">Obstet Gynecol. </span>1999;<span class="ref-vol">94</span>:1020–3.</span> [<a href="/pubmed/10576193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10576193</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.brigman.2006.484">Brigman C, Feranchak A. Liver involvement in cystic fibrosis. <span><span class="ref-journal">Curr Treat Options Gastroenterol. </span>2006;<span class="ref-vol">9</span>:484–96.</span> [<a href="/pubmed/17081482" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17081482</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.brock.1998.47">Brock DJ, Gilfillan A, Holloway S. The incidence of cystic fibrosis in Scotland calculated from heterozygote frequencies. <span><span class="ref-journal">Clin Genet. </span>1998;<span class="ref-vol">53</span>:47–9.</span> [<a href="/pubmed/9550361" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9550361</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.patient_registry.2011">CFF Patient Registry. Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation. Available <a href="http://www.cysticfibrosisdata.org/LiteratureRetrieve.aspx?ID=132652" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2011. Accessed 7-26-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.patient_registry.2013">CFF Patient Registry. Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation. Available <a href="https://www.cff.org/2013_CFF_Patient_Registry_Annual_Data_Report.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 7-26-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.cheng.2012.cd000222">Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2012;<span class="ref-vol">10</span>:CD000222.</span> [<a href="/pubmed/23076885" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23076885</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.chmiel.1999.823">Chmiel JF, Drumm ML, Konstan MW, Ferkol TW, Kercsmar CM. Pitfall in the use of genotype analysis as the sole diagnostic criterion for cystic fibrosis. <span><span class="ref-journal">Pediatrics. </span>1999;<span class="ref-vol">103</span>:823–6.</span> [<a href="/pubmed/10103316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10103316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.cuppens.1998.487">Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, Jorissen M, Droogmans G, Reynaert I, Goossens M, Nilius B, Cassiman JJ. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. <span><span class="ref-journal">J Clin Invest. </span>1998;<span class="ref-vol">101</span>:487–96.</span> [<a href="/pmc/articles/PMC508589/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC508589</span></a>] [<a href="/pubmed/9435322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9435322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.cutting.2015.45">Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. <span><span class="ref-journal">Nat Rev Genet. </span>2015;<span class="ref-vol">16</span>:45–56.</span> [<a href="/pmc/articles/PMC4364438/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4364438</span></a>] [<a href="/pubmed/25404111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25404111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.de_boeck.2005.e463">De Boeck K, Weren M, Proesmans M, Kerem E. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. <span><span class="ref-journal">Pediatrics. </span>2005;<span class="ref-vol">115</span>:e463–9.</span> [<a href="/pubmed/15772171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15772171</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.de_braekeleer.1997.208">De Braekeleer M, Allard C, Leblanc JP, Simard F, Aubin G. Genotype-phenotype correlation in cystic fibrosis patients compound heterozygous for the A455E mutation. <span><span class="ref-journal">Hum Genet. </span>1997;<span class="ref-vol">101</span>:208–11.</span> [<a href="/pubmed/9402971" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9402971</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.debray.2011.s29">Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. <span><span class="ref-journal">J Cyst Fibros. </span>2011;<span class="ref-vol">10</span> Suppl 2:S29–36.</span> [<a href="/pubmed/21658639" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21658639</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.desmond.2007.1402">Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. <span><span class="ref-journal">Liver Int. </span>2007;<span class="ref-vol">27</span>:1402–8.</span> [<a href="/pubmed/18036103" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18036103</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.d_rk.1997.365">D&#x000f6;rk T, Dworniczak B, Aulehla-Scholz C, Wieczorek D, B&#x000f6;hm I, Mayerova A, Seydewitz HH, Nieschlag E, Meschede D, Horst J, Pander HJ, Sperling H, Ratjen F, Passarge E, Schmidtke J, Stuhrmann M. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. <span><span class="ref-journal">Hum Genet. </span>1997;<span class="ref-vol">100</span>:365–77.</span> [<a href="/pubmed/9272157" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9272157</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.feldshtein.2010.713">Feldshtein M, Elkrinawi S, Yerushalmi B, Marcus B, Vullo D, Romi H, Ofir R, Landau D, Sivan S, Supuran CT, Birk OS. Hyperchlorhidrosis caused by homozygous mutation in CA12, encoding carbonic anhydrase XII. <span><span class="ref-journal">Am J Hum Genet. </span>2010;<span class="ref-vol">87</span>:713–20.</span> [<a href="/pmc/articles/PMC2978943/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2978943</span></a>] [<a href="/pubmed/21035102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21035102</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.ferec.2012.a009480">Ferec C, Cutting GR. Assessing the Disease-Liability of Mutations in CFTR. <span><span class="ref-journal">Cold Spring Harb Perspect Med. </span>2012;<span class="ref-vol">2</span>:a009480.</span> [<a href="/pmc/articles/PMC3543074/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3543074</span></a>] [<a href="/pubmed/23209179" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23209179</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.friedman.1995.1353">Friedman KJ, Teichtahl H, De Kretser DM, Temple-Smith P, Southwick GJ, Silverman LM, Highsmith WE Jr, Boucher RC, Knowles MR. Screening Young syndrome patients for CFTR mutations. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>1995;<span class="ref-vol">152</span>:1353–7.</span> [<a href="/pubmed/7551394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7551394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.gilljam.2004.174">Gilljam M, Moltyaner Y, Downey GP, Devlin R, Durie P, Cantin AM, Zielenski J, Tullis DE. Airway inflammation and infection in congenital bilateral absence of the vas deferens. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2004;<span class="ref-vol">169</span>:174–9.</span> [<a href="/pubmed/14551163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14551163</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.goss.2003.1460">Goss CH, Rubenfeld GD, Otto K, Aitken ML. The effect of pregnancy on survival in women with cystic fibrosis. <span><span class="ref-journal">Chest. </span>2003;<span class="ref-vol">124</span>:1460–8.</span> [<a href="/pubmed/14555580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14555580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.grody.2001.149">Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ, et al.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. <span><span class="ref-journal">Genet Med. </span>2001;<span class="ref-vol">3</span>:149–54.</span> [<a href="/pubmed/11280952" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11280952</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.groman.2004.176">Groman JD, Hefferon TW, Casals T, Bassas L, Estivill X, Des Georges M, Guittard C, Koudova M, Fallin MD, Nemeth K, Fekete G, Kadasi L, Friedman K, Schwarz M, Bombieri C, Pignatti PF, Kanavakis E, Tzetis M, Schwartz M, Novelli G, D'Apice MR, Sobczynska-Tomaszewska A, Bal J, Stuhrmann M, Macek M Jr, Claustres M, Cutting GR. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. <span><span class="ref-journal">Am J Hum Genet. </span>2004;<span class="ref-vol">74</span>:176–9.</span> [<a href="/pmc/articles/PMC1181905/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1181905</span></a>] [<a href="/pubmed/14685937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14685937</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.hamosh.1998.255">Hamosh A, FitzSimmons SC, Macek M Jr, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. <span><span class="ref-journal">J Pediatr. </span>1998;<span class="ref-vol">132</span>:255–9.</span> [<a href="/pubmed/9506637" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9506637</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.hodge.1999.329">Hodge SE, Lebo RV, Yesley AR, Cheney SM, Angle H, Milunsky J. Calculating posterior cystic fibrosis risk with echogenic bowel and one characterized cystic fibrosis mutation: avoiding pitfalls in the risk calculations. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">82</span>:329–35.</span> [<a href="/pubmed/10051167" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10051167</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.kerem.1997.35">Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. <span><span class="ref-journal">Genet Test. </span>1997;<span class="ref-vol">1</span>:35–9.</span> [<a href="/pubmed/10464623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10464623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.kiesewetter.1993.274">Kiesewetter S, Macek M Jr, Davis C, Curristin SM, Chu CS, Graham C, Shrimpton AE, Cashman SM, Tsui LC, Mickle J. A mutation in CFTR produces different phenotypes depending on chromosomal background. <span><span class="ref-journal">Nat Genet. </span>1993;<span class="ref-vol">5</span>:274–8.</span> [<a href="/pubmed/7506096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7506096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.knowles.2012.a009548">Knowles MR, Drumm M. The influence of genetics on cystic fibrosis phenotypes. <span><span class="ref-journal">Cold Spring Harb Perspect Med. </span>2012;<span class="ref-vol">2</span>:a009548.</span> [<a href="/pmc/articles/PMC3543075/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3543075</span></a>] [<a href="/pubmed/23209180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23209180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.leeuwen.2014.69">Leeuwen L, Fitzgerald DA, Gaskin KJ. Liver disease in cystic fibrosis. <span><span class="ref-journal">Paediatr Respir Rev. </span>2014;<span class="ref-vol">15</span>:69–74.</span> [<a href="/pubmed/23769887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23769887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.mak.1999.2217">Mak V, Zielenski J, Tsui LC, Durie P, Zini A, Martin S, Longley TB, Jarvi KA. Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia. <span><span class="ref-journal">JAMA. </span>1999;<span class="ref-vol">281</span>:2217–24.</span> [<a href="/pubmed/10376575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10376575</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.massie.2001.1195">Massie RJ, Poplawski N, Wilcken B, Goldblatt J, Byrnes C, Robertson C. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. <span><span class="ref-journal">Eur Respir J. </span>2001;<span class="ref-vol">17</span>:1195–200.</span> [<a href="/pubmed/11491164" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11491164</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.mckone.2003.1671">McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. <span><span class="ref-journal">Lancet. </span>2003;<span class="ref-vol">361</span>:1671–6.</span> [<a href="/pubmed/12767731" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12767731</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.moran.2010.2697">Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B, et al.  Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. <span><span class="ref-journal">Diabetes Care. </span>2010;<span class="ref-vol">33</span>:2697–708.</span> [<a href="/pmc/articles/PMC2992215/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2992215</span></a>] [<a href="/pubmed/21115772" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21115772</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.moran.2009.1626">Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. <span><span class="ref-journal">Diabetes Care. </span>2009;<span class="ref-vol">32</span>:1626–31.</span> [<a href="/pmc/articles/PMC2732133/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2732133</span></a>] [<a href="/pubmed/19542209" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19542209</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.moran.2014.65">Moran A, Pillay K, Becker DJ, Acerini CL, et al.  ISPAD Clinical Practice Consensus Guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents. <span><span class="ref-journal">Pediatr Diabetes. </span>2014;<span class="ref-vol">15</span> Suppl 20:65–76.</span> [<a href="/pubmed/25182308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25182308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.nick.2005.513">Nick JA, Rodman DM. Manifestations of cystic fibrosis diagnosed in adulthood. <span><span class="ref-journal">Curr Opin Pulm Med. </span>2005;<span class="ref-vol">11</span>:513–8.</span> [<a href="/pubmed/16217177" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16217177</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.noone.2000.1919">Noone PG, Pue CA, Zhou Z, Friedman KJ, Wakeling EL, Ganeshananthan M, Simon RH, Silverman LM, Knowles MR. Lung disease associated with the IVS8 5T allele of the CFTR gene. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2000;<span class="ref-vol">162</span>:1919–24.</span> [<a href="/pubmed/11069835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11069835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.oca.2009.2214">Oca F, Dreux S, G&#x000e9;rard B, Simon-Bouy B, de Becdeli&#x000e8;vre A, Ferec C, Girodon E, Muller F. Amniotic fluid digestive enzyme analysis is useful for identifying CFTR gene mutations of unclear significance. <span><span class="ref-journal">Clin Chem. </span>2009;<span class="ref-vol">55</span>:2214–7.</span> [<a href="/pubmed/19833837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19833837</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.palomaki.2002.90">Palomaki GE, Haddow JE, Bradley LA, FitzSimmons SC. Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians. <span><span class="ref-journal">Genet Med. </span>2002;<span class="ref-vol">4</span>:90–4.</span> [<a href="/pubmed/11882786" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11882786</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.prickett.2013.255">Prickett M, Jain M. Gene therapy in cystic fibrosis. <span><span class="ref-journal">Transl Res. </span>2013;<span class="ref-vol">161</span>:255–64.</span> [<a href="/pubmed/23273902" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23273902</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.rohlfs.2011.841">Rohlfs EM, Zhou Z, Heim RA, Nagan N, Rosenblum LS, Flynn K, Scholl T, Akmaev VR, Sirko-Osadsa DA, Allitto BA, Sugarman EA. Cystic fibrosis carrier testing in an ethnically diverse US population. <span><span class="ref-journal">Clin Chem. </span>2011;<span class="ref-vol">57</span>:841–8.</span> [<a href="/pubmed/21474639" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21474639</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.rosenstein.1998.589">Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. <span><span class="ref-journal">J Pediatr. </span>1998;<span class="ref-vol">132</span>:589–95.</span> [<a href="/pubmed/9580754" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9580754</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.scotet.2010.592.e1">Scotet V, Dugu&#x000e9;p&#x000e9;roux I, Audr&#x000e9;zet MP, Audebert-Bellanger S, Muller M, Blayau M, F&#x000e9;rec C. Focus on cystic fibrosis and other disorders evidenced in fetuses with sonographic finding of echogenic bowel: 16-year report from Brittany, France. <span><span class="ref-journal">Am J Obstet Gynecol. </span>2010;<span class="ref-vol">203</span>:592.e1–6.</span> [<a href="/pubmed/20932506" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20932506</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.sheridan.2005.3493">Sheridan MB, Fong P, Groman JD, Conrad C, Flume P, Diaz R, Harris C, Knowles M, Cutting GR. Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:3493–8.</span> [<a href="/pubmed/16207733" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16207733</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.sly.2013.1963">Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM. Risk factors for bronchiectasis in children with cystic fibrosis. <span><span class="ref-journal">N Engl J Med. </span>2013;<span class="ref-vol">368</span>:1963–70.</span> [<a href="/pubmed/23692169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23692169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.sosnay.2013.1160">Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J, Masica DL, Karchin R, Millen L, Thomas PJ, Patrinos GP, Corey M, Lewis MH, Rommens JM, Castellani C, Penland CM, Cutting GR. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. <span><span class="ref-journal">Nat Genet. </span>2013;<span class="ref-vol">45</span>:1160–7.</span> [<a href="/pmc/articles/PMC3874936/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3874936</span></a>] [<a href="/pubmed/23974870" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23974870</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.sun.2006.339">Sun W, Anderson B, Redman J, Milunsky A, Buller A, McGinniss MJ, Quan F, Anguiano A, Huang S, Hantash F, Strom C. CFTR 5T variant has a low penetrance in females that is partially attributable to its haplotype. <span><span class="ref-journal">Genet Med. </span>2006;<span class="ref-vol">8</span>:339–45.</span> [<a href="/pubmed/16778595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16778595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.wang.2002.2066">Wang Z, Milunsky J, Yamin M, Maher T, Oates R, Milunsky A. Analysis by mass spectrometry of 100 cystic fibrosis gene mutations in 92 patients with congenital bilateral absence of the vas deferens. <span><span class="ref-journal">Hum Reprod. </span>2002;<span class="ref-vol">17</span>:2066–72.</span> [<a href="/pubmed/12151438" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12151438</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.watson.2004.387">Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, Palomaki GE, Popovich BW, Pratt VM, Rohlfs EM, Strom CM, Richards CS, Witt DR, Grody WW. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. <span><span class="ref-journal">Genet Med. </span>2004;<span class="ref-vol">6</span>:387–91.</span> [<a href="/pmc/articles/PMC3110945/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3110945</span></a>] [<a href="/pubmed/15371902" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15371902</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.weiss.2005.1456">Weiss FU, Simon P, Bogdanova N, Mayerle J, Dworniczak B, Horst J, Lerch MM. Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. <span><span class="ref-journal">Gut. </span>2005;<span class="ref-vol">54</span>:1456–60.</span> [<a href="/pmc/articles/PMC1774703/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1774703</span></a>] [<a href="/pubmed/15987793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15987793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.welsh.2001">Welsh MJ, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <em>The Metabolic and Molecular Bases of Inherited Disease</em>. 8 ed. New York: McGraw-Hill; 2001:5121-88.</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.wilschanski.1995.705">Wilschanski M, Zielenski J, Markiewicz D, Tsui LC, Corey M, Levison H, Durie PR. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. <span><span class="ref-journal">J Pediatr. </span>1995;<span class="ref-vol">127</span>:705–10.</span> [<a href="/pubmed/7472820" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7472820</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.witt.1996.823">Witt DR, Schaefer C, Hallam P, Wi S, Blumberg B, Fishbach A, Holtzman J, Kornfeld S, Lee R, Nemzer L, Palmer R. Cystic fibrosis heterozygote screening in 5,161 pregnant women. <span><span class="ref-journal">Am J Hum Genet. </span>1996;<span class="ref-vol">58</span>:823–35.</span> [<a href="/pmc/articles/PMC1914676/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1914676</span></a>] [<a href="/pubmed/8644747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8644747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.yu.2012.25">Yu J, Chen Z, Ni Y, Li Z. CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis. <span><span class="ref-journal">Hum Reprod. </span>2012;<span class="ref-vol">27</span>:25–35.</span> [<a href="/pubmed/22081250" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22081250</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.zielenski.1995.777">Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. <span><span class="ref-journal">Annu Rev Genet. </span>1995;<span class="ref-vol">29</span>:777–807.</span> [<a href="/pubmed/8825494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8825494</span></a>]</div></li></ul></div><div id="cf.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="cf.REF.moskowitz.2005.739">Moskowitz SM, Gibson RL, Effmann EL. Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment. <span><span class="ref-journal">Pediatr Radiol. </span>2005;<span class="ref-vol">35</span>:739–57.</span> [<a href="/pubmed/15868140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15868140</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.rubenstein.2005.385">Rubenstein RC. Novel, mechanism-based therapies for cystic fibrosis. <span><span class="ref-journal">Curr Opin Pediatr. </span>2005;<span class="ref-vol">17</span>:385–92.</span> [<a href="/pubmed/15891431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15891431</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cf.REF.welsh">Welsh MJ, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <em>The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</em> New York: McGraw-Hill.</div></li></ul></div></div><div id="cf.Chapter_Notes"><h2 id="_cf_Chapter_Notes_">Chapter Notes</h2><div id="cf.Author_History"><h3>Author History</h3><p>Edith Cheng, MS, MD (2001-present) <br />James F Chmiel, MD; Case Western Reserve University School of Medicine (2008-2017) <br />Garry R Cutting, MD (2001-present) <br />Ronald L Gibson, MD, PhD; University of Washington (2001-2008) <br />Barbara A. Karczeski, MS, CGC, MA (2017-present)<br />Susan G Marshall, MD (2001-2004; 2017-present) <br />Samuel M Moskowitz, MD; Massachusetts General Hospital (2004-2017) <br />Thida Ong, MD (2017-present)<br />Darci Sternen, MS, LGC (2001-present) <br />Jonathan F Tait, MD, PhD; University of Washington (2001-2004)</p></div><div id="cf.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>2 February 2017 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 February 2008 (me) Comprehensive update posted to live Web site</div></li><li class="half_rhythm"><div>24 August 2005 (cd) Revision: changes to ACMG-recommended mutation panel</div></li><li class="half_rhythm"><div>24 August 2004 (me) Comprehensive update posted to live Web site</div></li><li class="half_rhythm"><div>26 March 2001 (me) Review posted to live Web site</div></li><li class="half_rhythm"><div>6 October 1998 (jt) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1250</span><span class="label">PMID: <a href="/pubmed/20301428" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301428</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/creatine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ctns/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1250&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1250/?report=reader">PubReader</a></li><li><a href="/books/NBK1250/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1250" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1250" style="display:none" title="Cite this Page"><div class="bk_tt">Ong T, Marshall SG, Karczeski BA, et al. Cystic Fibrosis and Congenital Absence of the Vas Deferens. 2001 Mar 26 [Updated 2017 Feb 2]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1250/pdf/Bookshelf_NBK1250.pdf">PDF version of this page</a> (547K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#cf.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#cf.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#cf.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#cf.Genetically_Related_Allelic_Disorders" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#cf.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#cf.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#cf.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#cf.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#cf.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#cf.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#cf.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7040[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TGFB1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1080[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CFTR</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2212[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FCGR2A</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1461110" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1461110" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1461110" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1461110" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301501" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Kidney Disease, Autosomal Recessive</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Kidney Disease, Autosomal Recessive<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sweeney WE, Avner ED. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24958810" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Heterogeneous spectrum of mutations in CFTR gene from Indian patients with congenital absence of the vas deferens and their association with cystic fibrosis genetic modifiers.</a><span class="source">[Mol Hum Reprod. 2014]</span><div class="brieflinkpop offscreen_noflow">Heterogeneous spectrum of mutations in CFTR gene from Indian patients with congenital absence of the vas deferens and their association with cystic fibrosis genetic modifiers.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sharma H, Mavuduru RS, Singh SK, Prasad R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Hum Reprod. 2014 Sep; 20(9):827-35. Epub 2014 Jun 23.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301489" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glycogen Storage Disease Type I</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glycogen Storage Disease Type I<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bali DS, Chen YT, Austin S, Goldstein JL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/9272157" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens.</a><span class="source">[Hum Genet. 1997]</span><div class="brieflinkpop offscreen_noflow">Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dörk T, Dworniczak B, Aulehla-Scholz C, Wieczorek D, Böhm I, Mayerova A, Seydewitz HH, Nieschlag E, Meschede D, Horst J, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hum Genet. 1997 Sep; 100(3-4):365-77. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24624459" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pancreatitis Overview</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pancreatitis Overview<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">LaRusch J, Solomon S, Whitcomb DC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301428" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301428" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041614dd21425a25151328">Cystic Fibrosis and Congenital Absence of the Vas Deferens - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Cystic Fibrosis and Congenital Absence of the Vas Deferens - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:08:20-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8CA65CE03FD1610000000009F90388&amp;ncbi_session=CE8CA65CE0416141_2553SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1250%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1250&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1250/&amp;ncbi_pagename=Cystic Fibrosis and Congenital Absence of the Vas Deferens - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CA65CE0416141_2553SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>